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1. AIM OF THE STUDY 
 
 
The balance between cell proliferation, differentiation and death during development 
is a key factor in the formation of the CNS. The identification of the genes that 
regulate developmental processes provides the opportunity to identify the molecular 
interactions that co-ordinate cell-cycle regulation with neural 
proliferation/differentiation and pattern formation in the CNS. 
Lost-on-transformation 1 (LOT1 also named ZAC1/PLAGL1) is a potential tumor 
suppressor gene with antiproliferative activity. LOT1 expression is lost in many types 
of human cancers and its forced expression in tumor derived cell lines leads to cell 
cycle arrest and induction of apoptosis.  
It has recently been shown that Lot1 is highly expressed during brain development. 
Notably, Lot1 expression is high in rat cerebellum in the early postnatal period, when 
neurogenesis of cerebellar granule cells (CGC) does take place, while its expression 
undergoes progressive decrease at later stages. Similarly, Lot1 is expressed in freshly 
plated proliferating CGC in culture with a progressive decrease of activity occurring 
in parallel with differentiation towards mature neuronal phenotype. While the 
available data suggest that Lot1 may play important an important role in reducing 
tumor progression, its physiological role in the processes of brain development still 
remains to be elucidated. By analogy, it is coneceivable that a role of Lot1 during 
periods at which neurogenesis is particularly prominent is to limit cell proliferation. 
Evidence from both in vivo and in culture studies indicates that neuronal precursor 
proliferation is negatively regulated by an increase in intracellular cAMP. The 
neuropeptide pituitary adenylate cyclase-activating polypeptide (PACAP) is a potent 
stimulator of cAMP production. In addition, it has been shown that PACAP regulates 
neurogenesis by exerting antimitogenic effect on neuronal precursors. The molecular 
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mechanisms by which the PACAP-cAMP system exerts its effects on neurogenesis 
are still largely unknown. The antiproliferative properties of Lot1 in tumor cells and 
its expression in proliferating neuronal precursors may indicate that Lot1 is one of the 
genes that are triggered by the cAMP cascade and that mediate the antiproliferative 
effects exerted by cAMP. The presence of a high density of PACAP receptors 
coupled to adenylate cyclase in the external granule cell layer of the rat cerebellum 
during early postnatal development, in a time period closely matching Lot1 
expression strongly suggests that Lot1 is regulated by the PACAP/cAMP system.  
Aim of the present study was to ascertain whether the expression of Lot1 occurring 
during proliferation of the cerebellar granule cells is induced by cAMP and to identify 
the molecular mechanisms that underlie Lot1 transcription. 
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2. INTRODUCTION 
 
 
2.1. LOT1/ZAC1/PLAGL1 
 
LOT1 (for lost-on-transformation and also named ZAC1 or PLAGL1) is a member of 
the a family of zinc-finger transcription factors, designated as PLAG family. Other 
members in this group include PLAG1 and PLAGL2, which share high homology 
with each other and with LOT1/ZAC1/PLAGL1. PLAG family members are 
structurally similar but appear to be functionally different. LOT1/ZAC1/PLAGL1 is a 
candidate tumor suppressor gene localized on human chromosome 6q24-25, a 
chromosomal region that is frequently deleted in many types of human cancers. 
PLAG1 is a protooncogene that is localized on chromosome 8q12 and was found to 
be a target of several types of chromosomal rearrangement in many tumors.  
 
 
2.1.1. PLAG genes cloning and nomenclature 
 
Lot1 was originally identified using a rat tissue culture model of ovarian cancer. In 
this model, a series of malignant rat ovarian surface epithelial (ROSE) cell lines were 
developed by spontaneous transformation from long term culture of progenitor cells. 
The malignant cells were examined for differentially expressed genes as compared to 
their corresponding normal progenitor cells. A cDNA, that was expressed in the 
normal cell line but not in its malignant counterpart, was cloned and named Lot1 
(accession number U72620) (Abdollahi et al., 1997a). Simultaneously, the human 
LOT1 sequence was cloned (accession number U72621) (Abdollahi et al., 1997b). 
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Zac1 (for Zinc-finger protein which regulates apoptosis and cell-cycle arrest; 
accession number X95503), which is the mouse orthologue of LOT1 and Lot1, was 
isolated by a functional expression cloning technique (Spengler et al., 1997). 
PLAG1 (for pleomorphic adenoma gene; GenBank accession number NM_002655) 
was discovered as a novel developmentally regulated gene at chromosome 8q12 and 
was found to be a main target of pleomorphic adenomas of the salivary gland. In 
these adenomas, frequent occurrence of t(3;8)(p21;q12) chromosomal rearrangement 
results in promoter swapping between PLAG1 and β-catenin and thus PLAG1 
constitutive expression (Kas et al., 1997). PLAGL2 (PLAG Like 2; another PLAG 
family member; accession number AF006005) was identified by database homology 
search (Kas et al., 1998). Recently the zebrafish orthologue of PLAG1 (AY864859), 
PLAGL2 (AF186476), and a novel member, PLAGX (AY864858) have been cloned 
(Pendeville et al., 2006).  
Gene symbol for the family member LOT1/ZAC1/PLAGL1 has been designated as 
PLAGL1 or Plagl1 by the Genome Nomenclature Committees based on the homology 
with the other members of PLAG family. Nevertheless in the past years different 
authors have named the human gene as LOT1, ZAC1 or PLAGL1, while the mouse 
and rat orthologues have been historically named Zac1 and Lot1 respectively. In this 
dissertation the symbols PLAGL1, LOT1, and ZAC1 all refer to the same human gene, 
while Lot1 and Zac1 refer to the rat and mouse orthologues respectively. 
 
 
2.1.2. LOT1/ZAC1 protein structure 
 
The human LOT1/ZAC1 gene spans at least 70 kb of the human genome on 
chromosome 6q24-25. The gene does not display a TATA box element (Abdollahi et 
al., 2003b). The LOT1/ZAC1 protein is encoded by exons 5 and 6, resulting in a large 
5’ UTR. The translation initiation codon (ATG) is mapped at the 326-bp downstream 
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from the beginning (5’ end) of exon 5, and the stop codon (TAA) is located at 1,238-
bp downstream from the 5’ end of exon 6, followed by about 1.2 kb of nucleotides 
including the poly(A) tail (Abdollahi et al., 2003b). Unlike the human ZAC1, which 
consists of 9 exons, the mouse Zac1 transcript is spliced from 10 exons (Varrault et 
al., 2001).  
The human LOT1/ZAC1 and rat/mouse orthologues share about 76.4% identity at the 
nucleotide level and 67.7% at the amino acid level. LOT1/ZAC1 encodes a 463 amino 
acid protein while rat and mouse orthologues encode a 583 and 704 amino acid 
protein respectively. Four domains common to human, mouse and rat can be 
identified: a seven C2H2-type zinc-finger motifs at the amino-terminal, a linker 
domain, a central region largely comprising repeats of proline, glutamic acid, and 
glutamine residues and a carboxyl terminal domain (Figure 2.1). These domains are 
rather well conserved (85.5%, 54%, 58%, and 63% identity, respectively) between 
human and rodent proteins. On the other hand rat and mouse orthologues display a 
clusters of glutamic acid residues within the carboxyl region that are absent in the 
human protein. Besides the mouse protein displays a central region containing 34 
proline-rich tripeptide repeats (PLE, PMQ, or PML), possibly important in protein–
protein interaction (Abdollahi et al., 1997a; Spengler et al., 1997; Varrault et al., 
1998). Despite these structural differences, the mouse and human LOT1/ZAC1 
proteins appear to have identical functional roles in apoptosis and growth inhibition 
(Varrault et al., 1998). An alternative splicing in the coding region of the human gene 
has been shown to result in the translation of a protein with five zinc fingers (instead 
of seven) named ZAC∆2 (Bilanges et al., 2001). 
 
 
2.1.3. Expression of LOT1/ZAC1  
 
Figure 2.1. Sequences of the LOT1/ZAC1 proteins. A) Sequence 
alignments of the LOT1/ZAC1 proteins. Human ZAC1 (hZAC), mouse 
Zac1 (mZac), and rat Lot1 (rLot) were aligned according to a Clustal
method. Residues that matched hZAC with one distance unit are boxed. 
B) Schematic representation of the LOT1/ZAC1 proteins structures. Each 
domain is indicated as a box: the seven zinc-finger of C2H2 type, the 
linker region, the proline repeats present in mZac only, the proline, 
glutamine and glutamic acid rich region, the glutamic acid clusters 
absent in hZAC, and the C terminus. The numbering of the amino acid 
residues is indicated below the boxes. C) Phylogenetic tree for 
LOT1/ZAC1 family. Only the zinc-finger domains were taken into 
account for the analysis. 
(Varrault et al., 1998)
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Expression during development. Zac1 transcripts appear to be abundantly expressed 
in many proliferative/differentiative areas during mouse brain development. At 
embryonic stages Zac1 is expressed in the neural tube from E9.5 (Tsuda et al., 2004), 
at later stages strong expression is observed in brain areas with active proliferation 
such as the ventricular zone and several neuroepithelius (Valente and Auladell, 2001). 
In addition, some differentiating areas, such as arcuate nucleus and amygdaloid 
region of the brain, are noticeably  labeled. From P0 onwards, the expression is 
evident in some proliferative areas, such as the subventricular zone (SVZ) and the 
external granular layer (EGL) of the cerebellum, as well as in Purkinje cells and in 
some synaptic areas characterized by high plasticity, such as the dorso and 
ventromedial hypothalamic nuclei, arcuate nucleus, ventral thalamic nucleus (Table 
2.1.) (Valente and Auladell, 2001; Valente et al., 2005).  
At the protein level Lot1-specific immunostaining has been observed at postnatal 
days 2–7 in the external granule layer (EGL) of rat cerebellum, which is composed 
primarily of proliferating neuronal precursor cells (Ciani et al., 2003). Purkinje cells 
showed distinct nuclear labelling at postnatal day 7, and at lower level, in adult 
cerebellum. It was also shown that primary cultures of cerebellar granule cells exhibit 
a temporal pattern of Lot1 expression resembling the one observed during in vivo 
development, with mRNA and protein levels progressively decreasing with 
differentiation (Figure 2.2.) (Ciani et al., 2003).  
Zac1 is broadly expressed in non neuronal embryonic tissues, being highly expressed 
in the liver primordium and the umbilical region (Piras et al., 2000). Zac1 is also 
expressed transiently in the myocardium and basal portion of the stratified embryonic 
epithelia (Tsuda et al., 2004) together with other embryonic sites (hindlimb, forelimb 
and somites) (Valente and Auladell, 2001).  
Analysis of cell types expressing Zac1 during mouse development revealed that the 
gene is expressed by progenitors of several tissues (brain, skeleton, and skeletal 
muscle). The intense expression of Zac1 in the progenitors of different cellular 
lineages during proliferation, before differentiation into postmitotic cells, suggests 
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that Zac1 plays an important role in the control of cell fate during neurogenesis and 
myogenesis (Valente et al., 2005).  
During postnatal development, Zac1 appears to be expressed in developing 
chondrogenic tissue (Tsuda et al., 2004; Valente et al., 2005). In this regard Zac1 was 
shown to be a potential regulatory gene involved in chondrogenic differentiation. 
During cartilage development, the pattern of Zac1 expression is associated with 
proliferating and pre-differentiating chondrocytes, while in mouse ATDC5 cells 
undergoing in vitro chondrogenesis, Zac1 mRNA appeared to be upregulated in 
parallel with genes expressed in the pre-cartilage stage but was low when type II 
collagen mRNA was markedly increased in differentiated cells (Tsuda et al., 2004).  
 
Expression in adult tissues. LOT1/ZAC1 is ubiquitously expressed in normal human 
tissues. The gene was shown to be variably transcribed in all the tissues examined: 
spleen, thymus, prostate, testis, ovary, intestine, colon, pituitary gland, kidney, 
placenta, adrenal gland, uterus, mammary gland, lung, lymphoid tissues, skeletal 
muscle, peripheral leucocytes, liver, whole brain, and spinal cord (Abdollahi et al., 
1997b; Bilanges et al., 1999; Kas et al., 1998; Varrault et al., 1998). In adult brain, 
the strongest signals were observed in the occipital lobe, cerebral cortex, and 
thalamus (Varrault et al., 1998). RNA in situ hybridization experiments have shown 
that LOT1/ZAC1 is expressed in normal mammary epithelial cells, most abundantly in 
the most luminal cells (Bilanges et al., 1999). LOT1/ZAC1 was also found to be 
strongly expressed in the human ovarian surface epithelium (which is the origin of 
most ovarian cancers) and in the follicle epithelial cells (Kamikihara et al., 2005).  
In adult mice the anterior pituitary gland showed the highest Zac1 expression, while 
lower level was observed in other brain areas such as olfactory bulb, cortex, 
hippocampus, hypothalamus-thalamus, brain stem and cerebellum, and faintly in 
stomach, kidney, adrenal gland, heart, and lung (Spengler et al., 1997). In the 
pituitary Zac1 mRNA was more abundantly expressed in the anterior lobe compared 
to the intermediate and posterior lobes. Zac1 transcripts were found in all hormone-
Table 2.1. Expression pattern of Lot1/Zac1 during mouse embryonic and 
postnatal development.                                          
(Valente and Auladell, 2001)
Table 2.1 (continued). Expression pattern of Lot1/Zac1 during mouse 
embryonic and postnatal development.                            
(Valente and Auladell, 2001)
AB
C
P2 P30
Figure 2.2. Expression of Lot1 during rat cerebellum development. A) 
Western blot analysis of Lot1 expression at different stages of
cerebellum development. B) Immunostaining for Lot1 on  rat cerebellum 
at postnatal day 2 and 30 (P2, P30) and in situ hybridisation for Lot1
mRNA (insert) at P2. EGL external granule layer; ML molecular layer; 
PC Purkinje cell layer; GC granule cell layer. C) Western blot analysis of 
Lot1 expression during in vitro differentiation of cerebellar granule cells 
(CGC) culture.
(Ciani et al., 2003)
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secreting cell types; with the highest levels in growth hormone (GH)- and prolactin 
(PRL)-producing cells (Pagotto et al., 1999). 
 
Expression in tumors and cancer cell lines. Reduction of the LOT1/ZAC1 gene 
expression was found to be a potential genetic event silencing the gene in cancers 
such as in breast and ovarian primary tumors and tumor-derived cell lines (Abdollahi 
et al., 1997a; Abdollahi et al., 1997b; Bilanges et al., 1999). The majority of human 
ovarian carcinoma cell lines examined showed decreased or undetectable LOT1/ZAC1 
expression (Abdollahi et al., 1997b). In agreement with the in vitro data, examination 
of ovarian carcinomas reduction of LOT1/ZAC1 expression that in more than 80% of 
the tumor tissues tested was of sizable extent, while in about 39% of ovarian cancer 
cases brought to no detectable expression (Cvetkovic et al., 2004). A recent study has 
confirmed the previous results showing a significant reduction in the mRNA 
expression level of this gene in 24 out of 28 primary ovarian cancer tissues, compared 
to the non-cancerous counterparts (Kamikihara et al., 2005). Primary breast tumors 
also showed reduced expression of this gene. Breast cancer cell lines compared to the 
normal mammary epithelial cells exhibited reduced LOT1/ZAC1 expression and more 
then 60% of the breast cancer cells examined showed complete loss of the gene 
expression (Bilanges et al., 1999). Also head and neck squamous cell carcinoma 
(HNSCC) cell lines exhibited downregulation of LOT1/ZAC1 expression compared to 
normal oral mucosa (Koy et al., 2004). It has also been suggested that LOT1/ZAC1 
gene downregulation in chondrocytes may be a significant contributing factor in the 
development of extraskeletal myxoid chondrosarcoma (EMC) tumors since 
LOT1/ZAC1 mRNA was found to be downregulated in EMC tumors (Poulin and 
Labelle, 2005). Besides, recent data suggest that LOT1/ZAC1 plays a role at an early 
stage of keratinocyte differentiation and in carcinogenesis (Basyuk et al., 2005). In 
normal skin, a high expression level of LOT1/ZAC1 was observed in basal 
keratinocytes and a lower expression in the first suprabasal differentiating layers of 
epidermis. Accordingly, in vitro, LOT1/ZAC1 was shown to be upregulated upon 
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induction of keratinocyte differentiation and was capable of triggering keratinocyte 
differentiation (Basyuk et al., 2005). LOT1/ZAC1 expression is dramatically lost in 
basal cell carcinoma, a neoplasm characterized by a relatively undifferentiated 
morphology; whereas, in squamous cell carcinoma that exhibits differentiated 
phenotype, LOT1/ZAC1 expression is maintained (Basyuk et al., 2005). LOT1/ZAC1 
may also play a role both in growth regulation and differentiation of pituitary gland 
(Pagotto et al., 2000). Indeed a strong reduction or absence of LOT1/ZAC1 mRNA 
and protein expression was detected in non-functioning pituitary adenomas, while in 
clinically active pituitary neoplasias, the decrease in LOT1/ZAC1 expression was 
variable (Pagotto et al., 2000). Taken together, the absence or reduced expression of 
LOT1/ZAC1 in majority of the tumor cells or tissues suggested the LOT1/ZAC1 
downregulation has a role in cancer. Accordingly, forced expression of LOT1/ZAC1 
into cancer cell lines, such as ovarian cancer cell lines (Abdollahi et al., 1999), the 
osteosarcoma cell line SaOs-2, and the porcine epithelial cell line LLC-PK1, both in 
vitro (culture) and in vivo (nude mice), inhibited cellular proliferation and induction 
of morphological transformation of tumor cells (Spengler et al., 1997). The anti-
proliferative activity of Zac1 was found to be due to induction of extensive apoptosis 
and of G1 arrest, which proceeded independently of retinoblastoma protein (Rb) and 
of expression of the cyclin dependent kinase inhibitors (CDKIs) p21Cip1, p27Kip1, 
p57Kip2, and p16INK4a (Spengler et al., 1997). It was also shown that Zac1-mediated 
apoptosis was unrelated to cell-cycle phase and the G1 arrest observed was 
independent of apoptosis, which suggested separate mechanism controlling apoptosis 
and cell-cycle arrest by Zac1 (Spengler et al., 1997). Furthermore, recent data have 
suggested that the LOT1/ZAC1-mediated apoptotic death in human ovarian cancer 
cells is p53-independent and can be blocked by caspases inhibitors (Kamikihara et al., 
2005). Downregulation of endogenous Zac1 expression by antisense treatment in two 
murine tumoral pituitary cell types, AtT-20 (anterior pituitary corticotrophin cell line) 
and TtT/GF (anterior pituitary folliculostellate cell line), that are representative of 
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granular and agranular cell lineages, respectively, increased cell proliferation in a 
dose-dependent manner (Pagotto et al., 1999).  
ZAC1 and its alternatively spliced variant, ZAC∆2, which lacks two zinc-finger 
domains, were both found to be nuclear proteins and equally efficient in preventing 
cell proliferation. However, the anti-proliferative activity of these variants is believed 
to result from a differential regulation of apoptosis versus cell cycle progression since 
ZAC∆2 was found to be more efficient in inducing cell cycle arrest than ZAC1, 
whereas the reverse was true for apoptosis induction (Bilanges et al., 2001).  
 
 
2.1.4. LOT1/ZAC1 gene regulation  
 
Chromosomal deletion in cancer. LOT1/ZAC1 is localized at human chromosome 
6q24-25, a chromosomal region known to harbor a tumor suppressor gene for several 
types of neoplasia (Wan et al., 1999). Analysis of allelic deletion in the tumor tissues 
provided additional evidence supporting a potential role for LOT1/ZAC1 in the 
pathogenesis of ovarian and breast cancer and possibly in other types of cancer. 
Ovarian and breast tumors showed about 36.4 and 40% loss of heterozygosity (LOH), 
respectively, of the LOT1/ZAC1 gene, based on allelic loss of one or more single 
nucleotide polymorphic sites within its genomic sequences (Cvetkovic et al., 2004). 
In another study, using primary squamous cell carcinomas of the head and neck 
(HNSCC) and microsatellite markers flanking LOT1/ZAC1, an average LOH rate of 
31.4% in the region was detected (Koy et al., 2004). Additionally, a recent study 
revealed a high frequency of 6q23-25 LOH in pheochromocytomas (PCCs) (Lemeta 
et al., 2006). Similarly, another report has concluded that in human hepatocellular 
carcinomas LOT1/ZAC1 is often silenced by allelic loss (Midorikawa et al., 2006). 
Together with its functional properties and chromosomal localization, these findings 
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substantiated LOT1/ZAC1 as a suitable candidate for the tumor suppressor gene 
localized at 6q24-q25. 
 
Epigenetic regulation in cancer. Alterations in the expression of LOT1/ZAC1 can 
occur also as a consequence of changes in epigenetic events. Analysis of LOT1/ZAC1 
genomic region revealed the presence of a CpG island in exon 1 that extends into the 
flanking promoter region of the gene (Abdollahi et al., 2003b; Arima et al., 2001; 
Varrault et al., 2001). This observation suggested that genomic DNA methylation is a 
mechanism of silencing the LOT1/ZAC1 gene expression. The hypothesis was tested 
in an in vitro reporter assay by modifying the LOT1/ZAC1 promoter region by DNA 
methylation, which resulted in a significant loss in the promoter ability to drive the 
reporter gene transcription in transfected cell lines (Abdollahi et al., 2003b; Arima et 
al., 2001; Varrault et al., 2001). Also, bisulfite sequencing of the genomic DNA 
showed that the LOT1/ZAC1 CpG island is a differentially methylated region (DMR) 
in ovarian and breast cancer cell lines or tumors samples (Abdollahi et al., 2003b). In 
these cell lines, the ratio of methylated to unmethylated CpG nucleotides in the DMR 
ranged from 31 to 99% and the ovarian tumors had relatively higher CpG methylation 
than in normal tissues. In similar studies, LOT1/ZAC1 mRNA expression was shown 
to be reduced in the majority of human ovarian cancer samples, which correlated with 
hypermethylation of the DMR (Kamikihara et al., 2005). It has also been observed 
that treatment with the methylation-interfering agent 5-azacytidine induced 
LOT1/ZAC1 re-expression in breast cancer cell lines (Bilanges et al., 1999). In 
addition to DNA methylation, epigenetic modification involving histone 
deacetylation may play an important role in transcriptional silencing and loss of gene 
function of LOT1/ZAC1. Trichostatin-A, a specific inhibitor of histone deacetylase 
(HDAC), was shown to relieve transcriptional silencing of LOT1/ZAC1 mRNA in 
malignantly transformed cells (Abdollahi et al., 2003b). Taken together, these data 
suggest that expression of LOT1/ZAC1 is under the control of two epigenetic 
modifications, CpG methylation and histone deacetylation and that, in the absence of 
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loss of heterozygosity, the maximal silencing of LOT1/ZAC1 may require both 
processes (Abdollahi et al., 2003b). 
 
Maternal imprinting regulation. In 1995, it was reported that transient neonatal 
diabetes mellitus (TNDM), a rare condition characterized by intrauterine growth 
retardation, dehydration, reduced postnatal development, and hyperglycemia due to a 
lack of normal insulin secretion, is associated with paternal uniparental disomy of 
chromosome 6 (UPD6), suggesting the involvement of an imprinted gene in this 
disease (Gardner et al., 1999; Temple et al., 1996; Temple et al., 1995). Genomic 
analysis of TNDM critical region for the presence of methylation differences between 
maternal and paternal alleles, using DNA from TNDM patients with paternal UPD6 
and normal controls, suggested LOT1/ZAC1 as a candidate imprinted gene for this 
disease (Gardner et al., 2000). Simultaneously, another report, identified LOT1/ZAC1 
as an imprinted gene and confirmed that this gene is expressed only from the paternal 
allele in a variety of tissues (Kamiya et al., 2000). Another study, using 
monochromosomal hybrid cells with a human chromosome 6 of defined parental 
origin, identified a novel maternally imprinted non-coding (untranslated) gene, 
HYMAI, in addition to LOT1/ZAC1. The HYMAI gene was found to be in close 
proximity of and partially overlapping with LOT1/ZAC1. This report also showed 
maternal imprinting of Zac1 in mice (Arima et al., 2000). This observation was 
confirmed by another report which identified Zac1 as an imprinted gene in mice that 
was expressed predominantly from the paternal allele in all adult mouse tissues tested 
(pituitary, ovary, lung, brain, and heart tissue) (Piras et al., 2000). In TNDM 
fibroblasts, the monoallelic expression of both LOT1/ZAC1 and HYMAI was found to 
be relaxed, which provided strong supportive evidence that the presence of two 
unmethylated alleles of this locus was indeed associated with the inappropriate gene 
expression of neighboring genes (Mackay et al., 2002). The DMR that partially 
overlaps mouse Zac1 and Hymai at the syntenic mouse locus is a likely imprinting 
control region (ICR) which is unmethylated in sperm but methylated in oocytes, a 
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difference that persists between parental alleles throughout pre- and post-implantation 
development (Arima et al., 2001). Within the ICR, there is a region that exhibits a 
high degree of homology between mouse and human. In the majority of TNDM 
patients with normal karyotype, there was a loss of methylation (LOM) within this 
highly homologous region, which suggested that epigenetic or genetic mutations of 
this region probably result in TNDM, possibly by affecting expression of 
LOT1/ZAC1 in the pancreas and/or the pituitary (Arima et al., 2001). Recently, a 
high-copy transgenic mouse line carrying the human TNDM locus has been 
developed, which displayed hyperglycemia in newborns and impaired glucose 
tolerance in adults mice (Ma et al., 2004). Expression of human LOT1/ZAC1 and 
HYMAI in these transgenic mice recapitulated key features of TNDM, implicating 
impaired development of the endocrine pancreas and beta cell function in 
pathogenesis of the disease (Ma et al., 2004).  
A recent report has confirmed the maternal imprinting of Zac1 using knockout mice. 
Expression of Zac1 protein was lost in both Zac1-/- homozygous mice and in 
heterozygous mice in which only the paternal allele was deleted (Zac1+/-pat) indicating 
the paternal origin of  Zac1 active allele and the silencing of the maternal allele 
(Varrault et al., 2006). Main phenotypic features of  Zac1-/- and Zac1+/-pat mice were 
intrauterine growth restriction, reduction of body weight, altered bone formation, and 
neonatal lethality, while Zac1+/-mat heterozygotes were indistinguishable from wild-
type pups. Interestingly while liver, hindlimb and lung were reduced in Zac1+/-pat 
mice, no absolute weight change was observed in brain (Varrault et al., 2006). The 
embryonic growth restriction phenotype observed in Zac1-deficient mice is 
counterintuitive. Indeed, it is generally observed that inactivation of genes promoting 
cell proliferation (e.g. oncogenes) leads to growth restriction, and inactivation of 
genes reducing cell proliferation (e.g., tumor suppressor genes) leads to overgrowth. 
It was therefore unexpected that the inactivation of Zac1, a putative tumor suppressor 
gene with proapoptotic and cell-cycle-blocking activities, resulted in embryonic 
growth reduction. On the other hand, accepted theory on imprinted genes, predicts 
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that paternally expressed imprinted genes are growth promoting, and maternally 
expressed genes are growth restraining (Moore and Haig, 1991; Wilkins and Haig, 
2003). The growth restriction phenotype of Zac1-deficient embryos shows that Zac1 
complies with this theory and accounts for the paternal expression of this 
antiproliferative gene (Varrault et al., 2006).  
 
Growth factor-dependent expression. LOT1/ZAC1 potential role in cancer and 
development was further supported by the evidence showing that this gene is a novel 
target of growth factor signaling pathways (Abdollahi et al., 1999). In normal ROSE 
cells, the Lot1 expression was strongly downregulated by epidermal growth factor 
(EGF) receptor ligands (Abdollahi et al., 1999; Abdollahi et al., 2003a). However, 
blocking the ligand-activated EGF receptor signal transduction pathway by a specific 
EGF receptor inhibitor (AG1478) or a mitogen-activated protein kinase (MEK) 
inhibitor (PD098059) restored the normal level of Lot1 expression, indicating that the 
signaling from the EGF receptor to Lot1 expression is relies upon MEK/ERK 
(extracellular-regulated protein kinase)  pathway. The EGF effect was also confirmed 
in human ovarian epithelial cells. In addition, the growth promoting agent 12-O-
tetradecanoylphorbol-13-acetate (TPA) was able to downregulate Lot1 expression 
(Abdollahi et al., 1999). Furthermore, a recent report showed that in rat pituitary 
tumor cells line GH3, the somatostatin analogue octreotide produces its 
antiproliferative action by inducing expression of Lot1 (Theodoropoulou et al., 2006). 
Octreotide inhibits cell proliferation by binding to a family of receptors (SSTR1-5), 
which belong to G-protein coupled receptors (GPCR). Knocking down Lot1 by RNA 
interference abolished the antiproliferative effect of octreotide in pituitary tumor 
cells, indicating that Lot1 is necessary for the action of octreotide. In this study Lot1 
expression appeared to be a target of the phosphatidylinositol 3-kinase (PI3-kinase) 
pathway. Octreotide treatment decreased the tyrosine phosphorylation levels of the 
PI3-kinase regulatory subunit p85, induced dephosphorylation of phosphoinositide-
dependent kinase 1 (PDK1) and protein kinase B (PKB/Akt), and activated glycogen 
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synthase kinase 3β (GSK3β). Therefore, in pituitary tumor cells, somatostatin 
analogues produce their antiproliferative action by acting on the PI3K/Akt/GSKβ 
signaling pathway and increasing Lot1 gene expression (Theodoropoulou et al., 
2006).   
 
 
2.1.5. Role of LOT1/ZAC1 as nuclear transcription factor  
 
The deduced amino acid sequences of the cDNAs for rat, mouse, and human 
LOT1/ZAC1, which contain C2H2-type zinc-finger domains at the N-terminal 
domain, suggested that they act as transcription factors (Abdollahi et al., 1997a; 
Abdollahi et al., 1997b; Kas et al., 1997; Spengler et al., 1997). Subsequent studies 
showed that the carboxyl terminal (the non-zinc-finger region) of these proteins can 
serve as an activator domain (Abdollahi et al., 1999; Kas et al., 1998). Lot1/Zac1 and 
p53 were found to be capable of inducing transcription of the PACAP type 1 receptor 
(PAC1-R) in different cell lines (Ciani et al., 1999; Hoffmann et al., 1998). In 
addition to both being capable of inducing PAC1-R expression, functional interaction 
between Zac1 and p53 was determined by investigating possible effects of Zac1 on 
the transcriptional activator function of p53 (Huang et al., 2001). Zac1 specifically 
enhanced the activity of p53-responsive promoters in cells expressing wild-type p53 
but not in cells lacking functional p53. The Zac1 effect was restored by coexpression 
of p53 in p53-null cells. The results suggested that Zac1 served as a transcriptional 
coactivator for p53 by directly binding to p53 (Huang et al., 2001). In addition, using 
luciferase-promoter construct, it has been shown that p53 is capable of activating 
Apaf-1, which can be enhanced by Zac1 (Rozenfeld-Granot et al., 2002). It is also 
believed that a sequence upstream to the first coding exon of Zac1 may contain a p53 
recognition site that is activated by p53 (Rozenfeld-Granot et al., 2002). Zac1 was 
also found to bind GRIP1, CREB-binding protein (CBP), and p300, and act as a 
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potent coactivator or repressor of nuclear receptors, including estrogen, androgen, 
glucocorticoid, and thyroid hormone receptor activity (Huang and Stallcup, 2000). In 
a more recent study, it has been shown that p300/CBP increases Zac1 transactivation 
in a strictly histone acetyltransferase (HAT)-dependent manner. The HAT activity is 
controlled by the coordinated binding of Zac1 zinc-fingers and carboxyl terminal 
region to p300, increasing the affinity for histone and acetyl-coenzyme-A (Hoffmann 
et al., 2006). The consensus DNA-binding site for LOT1/ZAC1 was identified as 
GGGGCCCC (Varrault et al., 1998). An alternatively spliced variant of ZAC1 
(designated as ZAC∆2), which lacks the sequence encoding the two N-terminal zinc-
finger domains, has been identified (Bilanges et al., 2001). Both ZAC1 and ZAC∆2 
were shown to localize in the nucleus, however, ZAC∆2 displayed an improved 
transactivation activity and an enhanced affinity for a ZAC1-binding site, which 
suggested that the two N-terminal zinc fingers negatively regulate ZAC binding to its 
target DNA sequences (Bilanges et al., 2001).  
 
 
 
2.2. CEREBELLUM DEVELOPMENT 
 
 
2.2.1. Overview of adult cerebellar cortex 
 
The cortex of the cerebellum is the region of the brain in which the most precise 
correlation between structure and function has been established. This brain region 
involved in the control of motor coordination, is composed of only eight different 
neuronal populations: six classical ones, already described by Cajal (1911), Purkinje 
cells, Golgi cells, Lugaro cells, granule cells, basket cells, stellate cells, and two more 
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recently reported ones, unipolar brush cells and candelabrum cells (Mugnaini and 
Floris, 1994). With the exception of unipolar brush cells that are much more 
numerous in ventral than dorsal lobules, the others repeat their specific pattern all 
along the numerous folia composing the cortex. This characteristic neuronal 
arrangement consists of a strict positioning of neurons and afferent fibers, conferring 
to the cortex a stereotyped three-dimensional geometry (Sotelo, 2004).  
In adult mammals and birds, the cortex of the cerebellum contains three main layers. 
The most superficial one is the molecular layer (ML), a region of low cellular density 
but of high synaptic density. The deepest layer exhibits, on the contrary, the highest 
cellular density of any central structure; it contains the granule cell neurons and is 
called the inner granular layer (IGL). At the interface between these two layers, a thin 
middle zone in which the cell bodies of the Purkinje cells are aligned into a single 
row can be found; this zone is the Purkinje cell layer (PCL). From the eight classes of 
neurons encountered in the cerebellar cortex only one, the Purkinje cell, has an axon 
which projects outside the cortex. The other seven populations are local circuit 
neurons (granule and unipolar brush cells are glutamatergic, and the five others 
GABAergic), and their axons never reach extracortical structures (Cajal, 1911; 
Mugnaini and Floris, 1994). Inhibitory interneurons are localized either in the ML 
(stellate, basket cells), in the PCL (candelabrum cells) or in the IGL (Lugaro, and 
Golgi cells) (Sotelo, 2004). 
 
 
2.2.2. Overview of cerebellar development.  
 
The cerebellum is derived from the dorsal plate of the neural tube and is part of the 
metencephalon. The cerebellum is one of the few exceptional structures in the brain 
where neuronal populations arise not from a single germinal zone but from at least 
two different germinal zones. The initial germinal matrix of the cerebellum is 
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bounded by the isthmus anteriorly and the choroid plexus posteriorly. The germinal 
matrix initially consists of a typical neuroepithelial ventricular zone and a more 
caudal germinal trigone region, also known as the rhombic lip. The first neurons to 
leave the ventricular zone are the nuclear neurons (embryonic days E10–12 in the 
mouse) that will settle deep to the cerebellar cortex. The birth and exit of Purkinje 
cells (E11–13 in the mouse) from the ventricular zone to form a temporary plate-like 
structure occur soon after the birth of the first nuclear neurons. The formation of a 
secondary germinal matrix from the rhombic lip, the external granular layer (EGL), 
occurs at about the time when nuclear and Purkinje cells have stopped dividing. The 
formation of the EGL is characterized by the migration of granule cells precursors 
(GCP) over the cerebellar surface in a subpial position. Postnatally, GCP proliferate 
extensively in the EGL and then migrate and differentiate into the developing IGL. 
Also generated at this time are the stellate and basket cells that colonize the ML. 
Granule cell migrate from the EGL to the IGL in an inward, radial manner helped in 
their journey by radial glial fibers (more properly known as the Bergmann fibers), 
through the molecular layer and past the developing Purkinje cells. It is during this 
time that the cerebellum is transformed from a curved structure into one with deep 
fissures and large finger-like appendages called folia. The EGL ceases to exist by the 
end of the second postnatal week in the mouse and the rat, and this period also sees 
the maturation of the two major extrinsic inputs to the cerebellar cortex: the inferior 
olive’s climbing fibers to the Purkinje cells and the spinal and reticular mossy fibers 
to the granule cells (Goldowitz and Hamre, 1998).  
 
 
2.2.3. Genetic dissection of the origins of the cerebellum.  
 
Traditionally, the cerebellum was believed to arise exclusively from the 
metencephalic territory of the developing neural tube (a region that extends 
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posteriorily from the choroid plexus to the constriction between the mesencephalon 
and metencephalon anteriorily, termed the isthmus). However, experimental studies 
using the chick–quail chimera system provided compelling evidence for a dual origin 
of the cerebellum. These studies demonstrated that the region of the neural tube that 
gives rise to the cerebellum not only includes the metencephalon, but extends 
anteriorily past the isthmus and into the caudal mesencephalon (Goldowitz and 
Hamre, 1998). The junction between the mesencephalon and metencephalon, the 
isthmus, has been shown to have an organizing potential on surrounding neural tissue. 
The special nature of the isthmic region is inherent in the number of important 
secreted and regulatory genes that are expressed in this region: Fgf8, Wnt1, En1, En2, 
Pax2, Pax5, Pax6, Pax8, Otx1, Otx2, Gbx2, Wnt5a and Nkx2.2. The isthmus is a 
transition region for the expression of many of these molecules (Joyner, 1996). For 
example, Fgf8 is expressed in the caudal portion of the isthmus, whereas Wnt1 is 
expressed rostrally, in a nonoverlapping, complementary fashion (Crossley and 
Martin, 1995). To attest the importance of these molecules, mutations or ectopic 
expression of several of these genes have marked impact upon cerebellar 
development. The best documented examples are Wnt1 and En1. Knockouts of these 
genes largely or totally eliminate the cerebellum (McMahon and Bradley, 1990; 
Thomas and Capecchi, 1990; Wurst et al., 1994). In mouse, as in fruit fly, it is 
believed that En1 expression is regulated by the secreted glycoprotein Wnt1 
(McMahon et al., 1992). The expression of these molecules might, in turn, be 
regulated by pairedbox-containing genes of the Pax family (Song et al., 1996). Indeed 
Pax2 is found to precede En1 and Wnt1 expression in the presomitic embryo. 
Inactivation of Pax2 leads to a frequent loss of the cerebellum and posterior midbrain 
(Favor et al., 1996). Another Pax gene that is expressed in the midbrain–hindbrain 
region is Pax5. Although deletions of Pax5 have little effect on cerebellar 
development, when a Pax5 knockout is complemented with a hemizygous deletion of 
Pax2 there is complete agenesis of the cerebellum in addition to the inferior colliculus 
(Urbanek et al., 1997). Also Pax6 appear an important player in cerebellum 
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morphogenesis as is mutation (Sey mouse) leads to cerebellum defects and 
perturbation of granule cells differentiation (Swanson et al., 2005). Other molecules 
that are expressed in the neighborhood of the isthmic region, namely Fgf8 and the 
homeodomain proteins Gbx2 and Islet3, are known to be important players in 
cerebellar development, as their elimination results in large deletions of the 
cerebellum (Kikuchi et al., 1997; Meyers et al., 1998; Wassarman et al., 1997). These 
three molecules are believed to act upstream to Wnt1 and En1. These results allow to 
start constructing a molecular framework of the initial development of the cerebellar 
anlagen. 
 
The contribution of the ventricular zone to neuronal populations in the cerebellum. 
The cells that colonize the cerebellum arise from either the ventricular 
neuroepithelium or the rhombic lip. The ventricular neuroepithelium is responsible 
for the generation of most of the neuronal populations within the cerebellum, 
including the nuclear, molecular layer, Purkinje and Golgi neurons. Fundamental 
questions are just being answered about the lineage relationships of these various 
neurons, although little is known about the cellular interactions and molecules that are 
crucial to commitment to each lineage. A recent report has found that all cerebellar 
neurons, with the exception of the granule cells, are clonally related. From this work 
it was concluded that Purkinje cells and nuclear cells arise from a common progenitor 
(Mathis and al., 1997). A further issue related to the ventricular epithelium concerns 
the generation of inhibitory interneurons (Golgi, stellate and basket cells). Until 
recently, the prevailing dogma was that GABAergic interneurons were generated in 
the secondary germinal zone (the EGL). This belief was based on the fact that the 
generation of both of these neuronal populations occurs postnatally and that the only 
substantive germinal zone at this time is the EGL. Recently, several lines of evidence 
make it clear that the formation of the GABAergic lineage occurs independently of 
the formation of the EGL. Using retroviral infections either superficially into the EGL 
or deep into the white matter of cerebellar cortex, it was found that injections into the 
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EGL generated only granule cells. Alternatively, injections into the white matter 
generated both astrocytes and GABAergic interneurons (Golgi, stellate and basket 
cells). Because the retrovirus is taken up only by cells undergoing mitosis, the 
molecular layer interneurons must undergo a round of mitosis within the white matter 
(Zhang and Goldman, 1996a; Zhang and Goldman, 1996b). This led to the hypothesis 
that the generation of inhibitory interneurons is a two-step process, with the initial 
generation occurring in the ventricular layer and subsequent migration into the white 
matter of the cerebellar cortex, where they undergo further cell division before 
translocation to their final destination. These findings were confirmed by a more 
recent report using mice expressing green fluorescent protein (GFP) from the Pax2 
locus (Weisheit et al., 2006). 
 
The contribution of the secondary germinal zone to the cerebellum. Granule cells 
have been recognized to arise from the secondary germinal zone since the time of 
Cajal (1911). Besides, he also reported that the EGL was composed of two distinct 
zones: a superficial one (the outer EGL), where granule cells precursors actively 
proliferate, and a deep zone (the inner EGL) containing undifferentiated postmitotic 
granule cells. The origin of granule cells has been confirmed by both retroviral 
labelling studies (Miyake et al., 1993; Ryder and Cepko, 1994a) and cell culture 
studies in which only granule cells were generated from cultured EGL cells (Gao and 
Hatten, 1994). Granule cell lineage is very clear: the cells all arise from the EGL, and 
the EGL appears to originate exclusively from the rombic lip (Goldowitz and Hamre, 
1998). A major finding that clarified the early development of the granule cell was 
the discovery that the helix–loop–helix (bHLH) transcription factor Math1 is essential 
for the establishment of the granule cell lineage. Mice with a knockout in the Math1 
gene lack all granule cells due to the absence of the formation of the EGL (Ben-Arie 
et al., 1997). The importance of Math1 in granule cell genesis was confirmed by 
overexpression of the gene in transgenic mice that resulted in perturbation of granule 
cell differentiation (Helms et al., 2001). Mechanisms regulating proliferation and 
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differentiation of GCP will be discussed in detail in a following section of this 
dissertation.   
 
 
2.2.4. Migration of cerebellar neurons  
 
The developing cerebellum can well serve as a model for most of the recognized 
ways by which neurons migrate in the CNS. There is an outward radial (Purkinje and 
nuclear neurons migrating from the ventricular zone) and inward radial migration 
(granule cells migrating from the inner part of the EGL to the IGL) (Altman and 
Bayer, 1997), as well as a circumferential (formation of the EGL) and tangential 
migration of cells (postmitotic granule cells in the inner part of the EGL) (Ryder and 
Cepko, 1994a). The initial migration in the cerebellum is the departure of the first 
cohorts of cells from the ventricular zone and germinal rhombic lip, which occurs at 
about E13 in the mouse. These migrating cells appear to define the future boundaries 
of the cerebellum. In Unc5h3 mutant mice (rostral cerebellar malformation, rcm 
mice) there is an exuberant migration of granule and Purkinje cells beyond the normal 
boundaries of the cerebellum into the inferior colliculus and hindbrain. Unc5h3 (the 
Caenorhabditis elegans unc-5 homologue) is a receptor for mouse Netrin (Ackerman 
et al., 1997; Leonardo et al., 1997). Netrin is found to be expressed in regions 
surrounding the cerebellum at E13 (Przyborski et al., 1998). Thus, there seem to be 
molecules that establish the normal boundaries of the cerebellum, with the proteins 
Netrin and its receptor, Unc5h3, as key players. On the other hand, Netrin signaling 
did not appear to be crucial for EGL formation (Bloch-Gallego et al., 1999).  
Two recently identified genes (reelin and disabled) that are known to be critical to 
neuronal migration in the cortex are also important for Purkinje cells migration. In 
mutant reeler and scrambler mice, caused by mutations in the extracellular matrix 
molecule Reelin (D'Arcangelo et al., 1995), and the tyrosine kinase signaling adaptor 
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molecule Disabled (encoded by Dab1) (Howell et al., 1997; Sheldon et al., 1997; 
Ware et al., 1997), respectively, Purkinje cells fail to migrate and largely remain in 
several ectopic clusters deep in the cerebellar cortex, while the granule cells appear to 
migrate normally but are greatly reduced in number (Goffinet et al., 1984; Goldowitz 
et al., 1997). While in neocortex there is a single population of Reelin-positive cells 
(the Cajal–Retzius cells) that are spatially juxtaposed to Dab1-positive cortical cells 
(Howell et al., 1997), in the cerebellum two populations of Reelin-positive cells have 
been identified: a subpopulation of cerebellar nuclear neurons and cells of the 
external granular layer. The responding cells in the cerebellum appear to be the 
Purkinje cells in that they both bind Reelin and express the Dab1 protein (Miyata et 
al., 1996). These two molecules are believed to be in the same molecular pathway 
with Dab1 downstream of Reelin (Goldowitz et al., 1997; Sheldon et al., 1997).  
Granule cells exhibit a two-stage migrating behavior in reaching their final 
destination. A tangential migration in the inner part of the EGL and a glial-guided 
radial migration across the ML to the IGL. The use of retrovirus in chick embryos has 
revealed that the unipolar and bipolar cells with “horizontal polarity” reported by 
Cajal (1911) in the inner EGL are tangentially migrating granule cells, that can move 
over a long distance, medially and laterally (Ryder and Cepko, 1994b). Tangential 
migration in the inner EGL has also been confirmed in slice preparations of P10 
mouse cerebellum using DiI labelling and time-lapse imaging (Komuro et al., 2001). 
Once tangential migration is completed, neurons in the deeper region of the EGL start 
to acquire a “vertical polarity” by emitting a new protoplasmic expansion, provided 
with a growth cone, which descends vertically from the basal pole of the cell body 
towards the white matter. The nucleus begins to descend within the vertical expansion 
once this third process penetrates into the forming ML (Cajal, 1911; Terrazas, 1897) 
(Komuro and Yacubova, 2003). Detailed electron microscopic study of granule cell 
migration across the molecular layer of the monkey cerebellum, reported that each 
descending expansion (the leading process) maintains an intimate contact with the 
vertically oriented Bergmann fibers (Rakic, 1971). Bergmann fibers are characterized 
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by the expression of a number of molecules, including nestin, brain-lipid-binding 
protein (BLBP), the antigens RC1 and RC2 and D4 (Soriano et al., 1997) that, 
together with other specific molecules, are required by the radial glial for supporting 
neuronal migration. The expression of these molecules is transient and, after the 
migration of granule cells is completed, Bergmann fibers lose their early features and 
become the radially oriented processes of mature astrocytes (the Golgi-Bergmann 
glia) (Sotelo, 2004). 
To date, large numbers of molecules and genes have been discovered as potential 
regulators or modulators of neuronal cell migration. Accordingly also granule cell 
migration is modulated by the action of many genes. One of such modulators appear 
to be brain-derived neurotrophic factor (Bdnf). Cerebellar granule cells express Bdnf 
and its high-affinity receptor (TrkB) (Wetmore et al., 1990). In vitro, Bdnf–/– granule 
cells initiate migration poorly and exogenous Bdnf induces both wild-type and Bdnf–/– 
cells to migrate. In vivo, a lack of Bdnf results in impaired migration of granule cells 
(Borghesani et al., 2002).  
9-O-acetyl-GD3 is a ganglioside expressed in the developing nervous system during 
periods of neuronal migration. Electron microscopic analysis reveals that 9-O-acetyl-
GD3 is localized at the contact sites between migrating granule cells and Bergmann 
fibers in the EGL and ML. Furthermore, the application of an antibody against 9-O-
acetyl-GD3, blocks the migration of cerebellar granule cells in a dose-dependent 
manner (Santiago et al., 2001). These results suggest that 9-O-acetyl-GD3 is involved 
in glia-associated migration of cerebellar granule cells in the developing ML.  
In the developing cerebellum, granule cells turn on the gene for tissue plasminogen 
activator (tPA) as they begin their migration into the ML (Friedman and Seeds, 
1995). Granule cells both secrete tPA (an extracellular serine protease that converts 
the proenzyme plasminogen into the active protease plasmin) and bind tPA to their 
cell surface. Interestingly, mice lacking the tPA gene (tPA–/–) have greater than 
twofold more migrating granule cells in the ML during a period of active cell 
migration. Granule cells in tPA–/– mice migrate through the ML at about half the rate 
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measured for migration of granule cells in tPA+/+ mice (Seeds et al., 1999). These 
findings suggest that tPA gene expression is required for maintaining the maximal 
rate of granule cell migration during cerebellar development.  
The human neuronal migration disorder Miller-Dieker lissencephaly, has been 
ascribed to a defect in Platelet-activating-factor (PAF) signaling (Jellinger and Rett, 
1976; Stewart et al., 1975). In this disorder, the brain has a smooth cortical surface 
(lissencephaly) caused by a lack of outer cortex complexity and a disruption of the 
migration of cerebellar granule cells (Jellinger and Rett, 1976; Miller, 1963; Stewart 
et al., 1975). This brain malformation results from a haploinsufficiency of the LIS-1 
gene (Ledbetter et al., 1992; Mizuguchi et al., 1995; Reiner et al., 1995), which 
encodes a 45-kDa subunit of a brain PAF acetylhydrolase, an enzyme that converts 
PAF to the inactive lyso-PAF (Hattori et al., 1994). It was found that the application 
of the non hydrolyzable PAF receptor agonist methyl-carbamyl-PAF (mc-PAF) 
yields a dose dependent decrease in cerebellar granule cell migration. This effect can 
be blocked by PAF receptor antagonists (Bix and Clark, 1998). Taken together, these 
results suggest that the stimulation of neuronal PAF receptors could be one critical 
step for the regulation of cerebellar granule cells as well as immature cortical 
neurons.  
Cyclin-dependent kinase 5 (Cdk5) is one unique member of the cyclin-dependent 
kinases (Meyerson et al., 1992). Unlike other cyclin-dependent kinases, which are 
known to control cell cycle in eukaryotes, Cdk5 expression and kinase activity are not 
associated to cell division. The appearance of active Cdk5 is correlated with the 
termination of neurogenesis and the beginning of differentiation of neuronal cells in 
the developing brain (Tsai et al., 1993). To elucidate the role of Cdk5 during postnatal 
cerebellar development, a series of Cdk5–/–-Cdk5+/+ chimeric mice have been 
generated, since Cdk5–/– mice die around birth and much cerebellar development 
occurs postnatally (Ohshima et al., 1999; Ohshima et al., 1996). In the Cdk5–/–-
Cdk5+/+ chimeric cerebella of 2- to 3-month old mice, significant numbers of granule 
cells are located in the ML, suggesting a failure to complete migration from the EGL 
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to the IGL. In fact, the granule cells found within the ML of chimeric cerebella are 
nearly all Cdk5 deficient. In contrast, the granule cells within the IGL are a mixture of 
Cdk5–/– and Cdk5+/+ cells (Ohshima et al., 1999). These results indicate that the block 
in cell migration that leaves many granule cells within the ML is intrinsic to Cdk5–/– 
cells, suggesting that Cdk5 may play crucial roles in cerebellar granule cell migration.  
Monitoring intracellular calcium levels using Ca2+ indicator dyes demonstrated that 
migrating granule cells exhibit dynamic changes inside the cell body  (Komuro and 
Rakic, 1998). Importantly, the reduction of Ca2+ influx by lowering extracellular Ca2+ 
concentrations or by blocking N-type voltage-gated Ca2+ channels results in a 
decrease in the amplitude and frequency of spontaneous Ca2+ elevations (Komuro and 
Rakic, 1996). This reduction is linearly related to a reduction in the rate of cell 
movement. Taken together, these results indicate that intracellular Ca2+ fluctuations 
provide an intracellular signal controlling granule cell migration.  
It has been also demonstrated an important role for N-methyl-D-aspartate (NMDA) 
receptor activation in the migration of granule cells from the EGL. The presence of 
spontaneous activity of the NMDA receptors on the surface of migrating cerebellar 
granule cells has been confirmed by patch-clamp analysis. The frequency of 
spontaneous NMDA receptor-coupled channel activity is low in the middle and the 
bottom of the EGL, but high in the ML (Rossi and N., 1993). Most importantly, 
blocking NMDA receptor activity with its antagonists significantly decreases the rate 
of granule cell movement in the ML. In contrast, the rate of cell migration is not 
substantially altered by blocking the activity of non-NMDA receptors (kainate and 
AMPA receptors), GABAA and GABAB receptors (Komuro and Rakic, 1993; 
Komuro and Rakic, 1996; Komuro and Rakic, 1998).  
The weaver (wv) mutation, a single base pair substitution in the G-protein-coupled 
inward-rectifying K+ channel protein Girk2 (Patil et al., 1995), appears to specifically 
affect the preparation of cells to migrate (Smeyne and Goldowitz, 1989). In this 
mutation, postmitotic and premigratory cells experience massive death. It is believed 
that the inactive Girk2 does not offer the compensatory hyperpolarization following 
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the predominant depolarizing current evoked by NMDA receptor activation 
(Surmeier et al., 1996). The result is sustained depolarization, excessive Ca2+ entry 
(Tucker et al., 1996) and cell death. Accordingly, abolishing of functional NMDA 
receptors in the weaver cerebellum rescues granule cells from death (Jensen et al., 
1999).  
At the cellular level it has been shown that granule cell survival is compromised and 
migration does not occur when radial glia are disordered and ‘atrophic’ (Rakic and 
Sidman, 1973; Ross et al., 1990). Additionally, it has been determined that, if glia are 
experimentally eliminated from the developmental cerebellum, GCP suffer large 
scale cell death (Delaney et al., 1996). On the other hand, using co-cultures of 
premigratory neurons and glial cells, it has been shown that the induction of the radial 
glial phenotype is in fact mediated by neuron-glial interactions (Hunter and Hatten, 
1995). The molecular underpinnings of this two-way interaction appear to be, on one 
hand, a neuron–glial trophic signal and, on the other, a glial–neuron buffering of the 
surrounding milieu. Astrotactin and Neuregulin are two molecules that are expressed 
in migrating cerebellar granule cells and provide a trophic support for glial 
development (Rio et al., 1997; Zheng et al., 1996). The EGF receptor tyrosine kinase 
family ErbB4 is known to be activated following Neuregulin stimulation. Neuregulin 
and ErbB4 are localized to granule cells and glia, respectively, this signaling pathway 
appears to be important to granule cell migration as well as the induction of radial 
glia morphology (Rio et al., 1997). Besides Astrotactin null mutation results in a 
decrease of the rate of granule cell migration, with increased apoptosis and secondary 
abnormalities in Purkinje cell development (Adams et al., 2002). 
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2.3. PROLIFERATION OF CEREBELLAR GRANULE 
CELLS 
 
 
2.3.1. Overview of neuron number regulation in the cerebellum 
 
The cerebellum is a highly ordered structure with a tight regulation of the ratio of 
Purkinje cells to granule cells (Wetts and Herrup, 1983). It appears that the number of 
Purkinje cells determines to a large extent the size of the granule cell population. 
Numerous mutations, as well as experimental perturbations, that eliminate Purkinje 
cells demonstrate that there is a concomitant reduction in the number of the granule 
cells (Goldowitz and Hamre, 1998). Transgenic mice in which subpopulations of 
Purkinje cells were ablated at various developmental times have been generated. In 
the EGL overlying areas of deleted Purkinje cells, the mitotic activity of EGL cells 
was significantly diminished relative to regions in which Purkinje cells were still 
present (Smeyne et al., 1995). This demonstrated that Purkinje cells can control the 
mitotic activity of GCP within the EGL. Support for this premise comes from a 
comparison of meander-tail/wild-type and weaver/wild-type chimeric mice 
(Goldowitz, 1989; Goldowitz and Mullen, 1982; Hamre and Goldowitz, 1997). In 
meander-tail mutant mice (gene symbol mea), cerebellar granule cells are largely 
depleted from the anterior cerebellum and somewhat compromised in the posterior 
lobe. In wv mutant mice, the generation of granule cells is normal and granule cells 
die after they become postmitotic. When the mutant gene acts early, as in mea, the 
chimeric cerebellum contains a near-normal number of granule cells in the anterior 
lobe as a result of repopulation by wild-type granule cells. In contrast, when the 
mutant gene affects postmitotic granule cells, as in wv, the chimeric cerebellum has a 
depletion in the granule cell population. These studies indicate a feedback mechanism 
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by which the EGL informs the Purkinje cells of the size of the population engaged in 
proliferation.  
 
 
2.3.2. Regulation of granule cells precursor proliferation 
 
The fact that Purkinje cells stimulate granule cell proliferation implies that some kind 
of mitotic signal must be generated from Purkinje cells. A good candidate for this 
role appeared to be the secreted glycoprotein Sonic hedgehog (Shh) which is 
expressed by Purkinje cells (Traiffort et al., 1999). Shh was known to be involved in 
limb skeletal development as well as cell proliferation and cell fate determination in 
many brain areas during development (Jensen and Wallace, 1997; Roelink et al., 
1995) (Ingham and McMahon, 2001; Litingtung et al., 2002; Palma, 2004; Wang et 
al., 2000). Besides granule cells in the EGL express Shh receptors and downstream 
effectors of Shh pathway (Corrales et al., 2004; Traiffort et al., 1999). This hypothesis 
received strong support by the demonstration that antibody-blocking of Shh action 
resulted in a marked reduction of granule cell production in vivo. In contrast, 
treatment with recombinant Shh prevented the GCP in culture to exit from the cell 
cycle and prolonged their proliferation (Dahmane and Ruiz-i-Altaba, 1999; Wallace, 
1999; Wechsler-Reya and Scott, 1999). This findings were confirmed later on by Shh 
conditional allele (L7-Cre and Pax2-Cre) knockout mice (Shh-/- mice die at birth) in 
which granule cell proliferation and cerebellum foliation are compromised (Lewis et 
al., 2004). Additionally transgenic mice overexpressing Shh display increased size of 
the cerebellum and prolonged proliferation of granule cells (Corrales et al., 2004). 
Shh receptor system is composed of two different proteins: Patched1 (Ptc1), a 12-
trasmembrane receptor for Shh and Smoothened (Smo) a 7-trasmembrane protein that 
mediates Shh downstream signals. In the absence of Shh, Ptc1 inhibits Smo activity 
but when Shh binds Pct1 the inhibition is released allowing activation of Smo (Fuse 
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et al., 1999; Kalderon, 2000). Through an unknown mechanism, activated Smo 
initiates a series of downstream events culminating in the activation of the Gli family 
of transcription factors (Gli1, Gli2, and Gli3) that control expression of Shh target 
genes. Shh signaling induces transcription, among other genes, of Ptc1 and Gli1, thus 
creating both negative and positive feedback effects (Goodrich et al., 1996; Marigo et 
al., 1996). Furthermore Gli1 transcription in response to Shh appear to be dependent 
on Gli2 or Gli3  with respect to the tissue analyzed. In the spinal cord Gli2 is the 
primary activator of Shh signaling, whereas Gli3 functions mainly (but not 
exclusively) as a repressor (Bai et al., 2002; Bai and Joyner, 2001; Bai et al., 2004; 
Persson et al., 2002). By contrast, in the limb Shh signaling inhibits Gli3 repressor 
and only Gli3 is required for digit patterning and for achieving normal level of 
proliferation (Litingtung et al., 2002; te Welscher et al., 2002; Wang et al., 2000). The 
three Gli genes, which display different patterns of expression in the cerebellum, 
appear to differently contribute to cerebellum development. Gli1-/- mice are viable, 
have a normal development and display altered Shh signaling only in combination 
with Gli2 heterozygosis (Park et al., 2000). In contrast Gli2-/- and Gli3-/- mice die at 
birth thus precluding evaluation of postnatal cerebellum development. Unlike Gli3 
mutants, Gli2-/- mice display a reduced thickness of the EGL at E18.5 (just before 
birth) and impaired transcription of Gli1 indicating a major role for Gli2 in 
transducing Shh signaling in the developing cerebellum (Corrales et al., 2004). 
Accordingly Gli2 conditional allele (En1-Cre) mutants, in which the target gene is 
deleted from E9 in the cells that will give rise to the cerebellar cortex are viable and 
display reduced size of the cerebellum and a premature cessation of proliferation in 
the EGL (Corrales et al., 2006). Importantly, elevation of intracellular cyclic 
adenosine monophosphate (cAMP) levels and subsequent protein kinase A (PKA) 
activation inhibits Shh signaling (Concordet et al., 1996; Dahmane and Ruiz-i-Altaba, 
1999; Kenney and Rowitch, 2000; Wallace, 1999; Wechsler-Reya and Scott, 1999) 
possibly by enhancing Gli3 repressor activity (Dai et al., 1999) and/or promoting 
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cAMP responsive element-binding protein (CREB) phosphorylation (Pons et al., 
2001).   
The major target gene involved in proliferation that is directly upregulated in granule 
cells in response to Shh signaling is the protooncogene Nmyc (Kenney et al., 2003; 
Oliver et al., 2003). Nmyc in turns enhances D-type cyclins (CcnD1 and CcnD2) 
expression, promotes GCP proliferation and prevents their differentiation (Kenney et 
al., 2003; Kenney and Rowitch, 2000; Knoepfler et al., 2006; Oliver et al., 2003). 
Accordingly, the cerebellum is reduced in Nmyc conditional allele (Nestin-Cre) 
knockout mice (Nmyc mutant dye during gestation) and granule cells proliferation in 
response to Shh signaling is inhibited in cultures obtained from this mutant (Hatton et 
al., 2006; Knoepfler et al., 2006). This results clearly indicates Nmyc as a downstream 
effector of Shh signaling in the cerebellum. Besides other pathways may give 
important contribution in supporting GCP proliferation by synergize with Nmyc. For 
example it has been shown that PI3-kinase pathway activation  enhances granule cell 
precursor proliferation by stabilizing Nmyc protein via activation of Akt and 
subsequent inhibition of GSK3β-dependent Nmyc phosphorylation and degradation. 
The effects of PI3-kinase activity on Nmyc stabilization are mimicked by insulin-like 
growth factor (IGF), an activator of PI3-kinase cascade which have been shown to 
have a role in central nervous system precursor proliferation (Kenney et al., 2003b). 
These findings indicate that Shh and PI3-kinase signaling pathways converge on 
Nmyc to regulate neuronal precursor cell cycle progression. 
 
 
2.3.3. Regulation of granule cells precursor differentiation  
 
As stated above GCP proliferate in the outer EGL under the influence of mitogenic 
Shh secreted by Purkinje cells and then translocate in the inner EGL where they cease 
proliferation and begin differentiation. An obvious question arise from this behavior: 
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what are the mechanisms that drive the exit from cell cycle of granule cell precursor 
and initiate their differentiation program? Several explanations have been proposed to 
answer this question involving the action of extracellular matrix (ECM) components, 
cell-cell interactions or diffusible signals.  
A first explanation comes from the observation that, in the prenatal and early 
postnatal cerebellum, stromal cell-derived factor 1α (SDF-1α) is expressed by cells 
in the pia membrane, while GCP and immature granule cells express its Gαi-coupled 
receptor CXCR4 (Zou et al., 1998). Importantly, the deletion of SDF-1α or CXCR4 
leads to the premature migration of GCP away from the proliferative zone of the EGL 
and small numbers of GCP are found ectopically outside the EGL of SDF-1α- or 
CXCR4-deficient mice (Ma et al., 1998; Zou et al., 1998). Accordingly, SDF-1α has 
been found to induce chemotactic responses in GCP (Klein et al., 2001). These results 
suggest that SDF-1α and CXCR4 play a crucial role in retaining GCP in the EGL. 
Besides SDF-1α signaling has also been found to enhance Shh mediated proliferation 
of GCP, probably by inhibiting, through Gαi, cAMP production by adenylate cyclase 
and therefore reducing PKA activity, which is known to repress Shh mediated 
proliferation (Klein et al., 2001). Although the expression of SDF-1α or CXCR4 
persists during the early postnatal cerebellum, postmitotic granule cells initiate their 
migration toward the IGL. A possible molecular mechanisms that explains this 
behavior have been proposed. Ephrin-B2 and its receptor EphB2 are expressed in the 
developing EGL. The chemoattractant effect of SDF-1α to the granule cells is 
selectively inhibited by soluble EphB2 receptor through reverse signaling of Ephrin-
B2 (Lu et al., 2001). These results suggest that when granule cells are ready to 
migrate, they would lose responsiveness to SDF-1α. Such changes in responsiveness 
to SDF-1α could be mediated at least in part by EphB2 receptor and Ephrin-B2.  
A second explanation to the fact that GCP exit the cell cycle in the inner part of the 
EGL, just as they approach Purkinje cells, the putatively primary source of mitogenic 
Shh, has been ascribed to pituitary adenylate cyclase-activating polypeptide (PACAP) 
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signaling. The neuropeptide PACAP is expressed by Purkinje cells, deep cerebellar 
nuclei while PACAP immunoreactivity has been detected in nerve fibers in the EGL, 
during cerebellum development. On the other hand granule cells express PACAP 
receptor 1 (PAC1-R) in the EGL with an increased abundance in its inner part (Nicot 
et al., 2002; Nielsen et al., 1998; Skoglosa et al., 1999). In contrast Gli1 appears to be 
expressed mainly in the outer EGL (Nicot et al., 2002). PACAP signaling, through 
PAC1-R coupled to protein Gs, stimulates cAMP production by adenylate cyclase 
thus inhibiting Shh mediated proliferation of granule cell (Nicot et al., 2002). By 
contrast SDF-1α secreted by the pia inhibits cAMP production and enhances Shh 
mediated proliferation (Klein et al., 2001). In this scenario it has been proposed that 
PACAP, through cAMP elevation and PKA activation, could antagonize Shh and 
SDF-1α signaling in the inner EGL, leading to exit from the cell cycle and initiation 
of differentiation of granule cells (Nicot et al., 2002). The observation that Gli1, a 
marker of Shh signaling, is expressed in the outer EGL, while PAC1-R, that mediate 
PACAP antiproliferative effects, is mainly found in the inner EGL together with 
CREB phosphorylation (Pons et al., 2001), is consistent with this theory (Figure 2.3).  
An alternative explanation has been provided by the observation that some ECM 
components are differentially represented in the inner and outer EGL. Laminin and its 
receptors (α6 integrins) are highly expressed in mitotically active GCP in the outer 
EGL, whereas vitronectin and its major receptors (αv integrins) are expressed in 
postmitotic cells in the inner EGL and in the IGL. Besides this pattern of expression 
appears to have a functional role in granule cell proliferation: cells cultured on 
laminin responded much more strongly to Shh-induced proliferation than cells 
cultured on vitronectin, which, in addition, expresses differentiation markers. 
Apparently vitronectin, initiates an intracellular signaling cascade that changes the 
response of granule cells to Shh. The pathway in GCP, responsible for the conversion 
from a proliferative Shh-mediated response to a differentiation signal, appear to 
depend on CREB. Vitronectin stimulates phosphorylation of CREB, and over-
Figure 2.3. Model of PACAP regulation of granule precursor 
proliferation. Granule precursors are depicted in the outer EGL (A) and 
inner EGL (B), with the complex of soluble, extracellular signals and 
their receptors, including Shh/Ptc-Smo, SDF-1/CXCR4, and 
PACAP/PAC1-R. A) Near the pia matter during the first postnatal week, 
granule cell proliferation is high. Prominent expression of SDF-
1/CXCR4 blocks adenylate cyclase activity and cAMP via Gαi coupling, 
thereby promoting Shh-induced proliferation. B) In the inner EGL as 
development progresses, SDF-1 and CXCR4 levels decrease. In turn, the 
proliferative action of Shh is now blocked by PACAP via Gs activation 
of adenylate cyclase through PAC1 receptors. PACAP may be derived 
from nerve fibers emerging from the Purkinje layer or brainstem nuclei. 
ML, Molecular layer; PL, Purkinje cell layer; PM, pia matter.
(Nicot et al., 2002)
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expression of CREB appears to be sufficient to induce granule cell differentiation in 
the presence of Shh. Taken together, these data suggest that granule neuron 
differentiation is regulated by the vitronectin-induced phosphorylation of CREB, a 
critical event that terminates Shh-mediated proliferation and permits the 
differentiation program to proceed in these cells (Pons et al., 2001).  
While mitogenic signaling by Shh appears to be the main source driving granule cell 
proliferation, the mechanisms regulating exit from cell cycle and differentiation of 
GCP appear to be intricate and not yet fully understood. It is also possible that 
different mechanisms may contribute in parallel in regulating this process possibly 
converging on PKA activation and CREB phosphorylation.      
 
 
 
2.4. PITUITARY ADENYLATE CYCLASE ACTIVATING 
POLYPEPTIDE 
 
 
Pituitary adenylate cyclase-activating polypeptide (PACAP) was first isolated from 
ovine hypothalamic extracts on the basis of its ability to stimulate cyclic adenosine 
monophosphate (cAMP) formation in anterior pituitary cells (Miyata et al., 1989). 
PACAP is produced by both hypotalamic neurons and other neurons in the CNS as 
well as by many peripheral tissues. PACAP has been found to exert pleiotropic 
effects including modulation of neurotransmitter release, vasodilation, 
bronchodilation, activation of intestinal motility, increase of insulin and histamine 
secretion, as well as stimulation of cell multiplication and/or differentiation (Vaudry 
et al., 2000a).  
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2.4.1. PACAP peptides and regulation 
PACAP exists in two forms, a longer 38- and a shorter 27-amino acid peptides 
(PACAP-38 and PACAP-27) (Miyata et al., 1990) whose sequences appear to be 
highly conserved along evolution (Vaudry et al., 2000a). The human PACAP cDNA 
encodes a 176-amino acid prepro-protein with a N-terminal 24-amino acid signal 
peptide (Hosoya et al., 1992). In mammals (human, sheep, rat and mouse) PACAP 
precursor comprises both PACAP and a second peptide termed PACAP-related 
peptide (PRP) located upstream (Vaudry et al., 2000a). By the action of different 
enzymes (prohormone convertases, carboxypeptidases and peptidyl glycine α-
amidating monooxygenase) PRP, PACAP-38 and PACAP-27 are generated from the 
precursor (Li et al., 1999; Okazaki et al., 1992; Vaudry et al., 2000a). The sequence 
of human PACAP-27 is 68% identical to vasoactive intestinal polypeptide (VIP), 
identifying PACAP as a member of the VIP-growth hormone releasing factor (GRF)-
glucagon-secretin superfamily (Campbell and Scanes, 1992). 
The human PACAP gene is composed of five exons with a promoter sequence 
comprising two regions, termed P1 and P2, which correspond, respectively, to an 
initiator-like sequence and a CT-rich domain with GC boxes. Besides, the PACAP 
promoter possesses two cAMP-response elements (CRE), a 12-O-
tetradecanoylphorbol-13-acetate (TPA) response element (TRE) and a pair of 
sequences homologous to the consensus sequence for pituitary-specific growth 
hormone factor 1 (GHF-1) binding sites, which is known to play a role in the tissue 
specific expression of growth hormone (GH) (Vaudry et al., 2000a). Investigation of 
the promoter activity has revealed that PACAP is constitutively expressed and that 
transcription of the PACAP gene can be enhanced by cAMP, TPA and even by 
PACAP itself  (Suzuki et al., 1994).  
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2.4.2. PACAP expression in the CNS 
  
During rat development PACAP mRNA is expressed from E13 in distinct regions of 
rodent brain: developing cortex, hippocampus, amygdala and hypothalamus as well 
as in spinal cord and dorsal root ganglia (Skoglosa et al., 1999). In adult rat brain 
PACAP appears to be highly expressed in the hypothalamus in particular in the 
magnocellular neurons of paraventricular (PVN) and supraoptic (SON) nuclei 
(Arimura et al., 1991; Hannibal et al., 1995a; Hannibal et al., 1995b; Koves et al., 
1991; Skoglosa et al., 1999). Dense accumulation of PACAP-immunoreactive fibers 
is found in the internal zone of the median eminence and in the vicinity of the 
capillaries of the hypothalamo-hypophysial portal system (Hannibal et al., 1995a). 
Significant amounts of PACAP-38 are also found in extrahypothalamic regions, 
including the substantia nigra, nucleus accumbens, septum, globus pallidus, cerebral 
piriform cortex, and pons (Ghatei et al., 1993; Masuo et al., 1993). In the limbic 
system, PACAP-immunoreactive fibers are detected in the amygdaloid complex and 
in the mediodorsal and paraventricular nuclei of the thalamus (Koves et al., 1991; 
Masuo et al., 1993). In the lateral septum area, a dense network of immunoreactive 
fibers innervates blood vessels (Koves et al., 1991). PACAP and its mRNA have also 
been detected in the cerebellum (Purkinje cells and deep cerebellar nuclei) (Ghatei et 
al., 1993; Hannibal et al., 1995a; Nielsen et al., 1998; Skoglosa et al., 1999). 
Specifically, PACAP immunoreactivity is localized in the soma and dendrites of 
Purkinje cells, whose axons directly contact granule cells precursors proliferating in 
the EGL (Nielsen et al., 1998).  
 
 
2.4.3. PACAP receptors 
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Two classes of PACAP receptors have been identified so far in mammals on the basis 
of their different affinity for PACAP and VIP. Type I PACAP receptors (PAC1-R) 
have high affinity for PACAP (Kd ~ 0.5 nM) and low affinity for VIP (Kd ~ 500 nM), 
whereas type II (VPAC1-R and VPAC2-R) have similar affinity for both PACAP and 
VIP (Kd ~ 1 nM)(Vaudry et al., 2000a).  
PAC1-R are G protein-coupled receptor that can activate either phospholipase C 
(PLC) or adenylate cyclase (AC). Adenylate cyclase activation leads to cAMP 
production whereas PLC activation leads to inositol triphosphate (IP3) and 
diacylglycerol (DG) production and subsequent Ca2+ mobilization and protein kinase 
C (PKC) activation. The coupling of PAC1-R to distinct second messenger appear to 
depend upon different splice variants of the receptor. The presence of alternative 
cassettes in the third intracellular loop of the receptor (Hip and Hop variats) confers 
AC or PLC responsiveness (Journot et al., 1994; Spengler et al., 1993). On the other 
hand VPAC receptors have been found to activate only adenylate cyclase to produce 
cAMP (Vaudry et al., 2000a). 
In the brain the expression of PAC1-R is generally higher than VPAC receptors. 
PAC1-R transcripts appear to be particularly abundant in the olfactory bulb, the 
dentate gyrus of the hyppocampus, the supraoptic nuclei of the hypothalamus, the 
cerebellar cortex, and the area postrema. High levels of PAC1-R mRNA have been 
also found in the cingulate, entorhinal and piriform cortex, pyramidal and 
nonpyramidal cells of the hippocampal formation, the amygdaloid nuclei, the 
centromedial, mediodorsal, and ventromedial nuclei of the thalamus, the 
hypothalamus, the central gray, the raphe nuclei, and the superior colliculus (Vaudry 
et al., 2000a). VPAC1-R are expressed mainly in the cerebral cortex, hippocampus 
and olfactory bulb while VPAC2-R are found in the thalamus, suprachiasmatic 
nucleus, central nucleus of the amygdala, pontine nucleus hippocampus and olfactory 
bulb (Vaudry et al., 2000a). During rodent brain development PAC1-R are expressed 
from E9.5 in the neural tube and at later stages in all proliferating neuroephitelia 
(Vaudry et al., 2000a). During postnatal rat cerebellum development PAC1-R are 
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found initially in the proliferating EGL and then in the ML and IGL (Basille et al., 
1994). A similar distribution during brain development has been found for VPAC1-R 
while VPAC2-R transcripts appear to be more abundant in the thalamus and 
hypothalamus (Vaudry et al., 2000a). 
 
 
2.4.4. Effects of PACAP in  the CNS 
 
Due to its broad distribution in the CNS, it is not surprising that  PACAP has been 
shown to exert multiple function in the different areas. In the hypothalamus, where 
the highest expression of both PACAP and its receptors has been detected, the 
peptide appears to activate and increase firing of magnocellular neurons of the PVN 
and SON. PACAP also modulates the activity of other hypothalamic population 
enhancing the expression of gonadotropin-releasing hormone (GnRH), somatostatin, 
prolactin (PRL) and corticotropin-releasing factor (CRF) (Vaudry et al., 2000a). 
PACAP has also been involved in circadian clock regulation in the suprachiasmatic 
and supraoptic nuclei as well as rhythmic melatonin release in the pineal gland. This 
latter action appears to depend upon Ca2+ influx and CREB phosphorylation (Vaudry 
et al., 2000a). In the pituitary neural lobe PACAP appears to stimulate the release of 
vasopressin and oxytocin through cAMP/PKA signalling. PACAP has also been 
shown to stimulate the release from the anterior pituitary of growth hormone (GH), 
adrenocorticotropic hormone (ACTH), luteinizing hormone (LH), follicle-stimulating 
hormone (FSH), prolactin (PRL) but not of thyroid-stimulating hormone (TSH). 
Besides it has also been shown that PACAP increases secretion of melanotropin α-
melanocyte-stimulating hormone (α-MSH) from melanotrope cells of the 
intermediate lobe of the pituitary. The action of PACAP on secreting cells in the 
pituitary is mediated via cAMP production and/or Ca2+ mobilization (Vaudry et al., 
2000a). 
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PACAP has also been found to exert nurotrophic effects on neurons. The peptide 
appears to protect cerebellar granule cells and cortical neurons from programmed cell 
death when cultured in apoptosis promoting conditions (Gonzalez et al., 1997; Morio 
et al., 1996). The protective effects of PACAP on cerebellar granule neurons appears 
to depend on cAMP production from adenylate cyclase and subsequent PKA 
activation (Gonzalez et al., 1997; Villalba et al., 1997). Besides, it has been suggested 
that the anti-apoptotic action of PACAP via cAMP/PKA transduction pathway, 
involves inhibition of delayed outward rectifier K+ current and long-term 
depolarization of the resting membrane potential (Mei et al., 2004). The 
neuroprotective action of PACAP has also been demonstrated in vivo where is able to 
prevent ischemic death of hippocampal neurons (Uchida et al., 1996). 
The presence of high levels of PACAP and its receptors in germinative areas during 
brain development suggests that the peptide might be involved in the regulation of 
CNS morphogenesis. PACAP has been found to reduce proliferation and promote 
differentiation of cortical neuron precursors (Lu and DiCicco-Bloom, 1997), to 
antagonize Shh mitogenic signalling on cerebellar granule precursors and stimulate 
neurite outgrowth of cerebellar granule neurons (Gonzalez et al., 1997; Nicot et al., 
2002). On the contrary PACAP appears to stimulate proliferation of sympathetic 
neuroblasts (Lu and DiCicco-Bloom, 1997). Opposite effects on neuroblasts 
proliferation appear to depend upon differential coupling of PACAP receptors to PLC 
or adenylate cyclase second messenger cascade. PLC coupled PAC1-R Hop variant 
expression appears to stimulate proliferation whereas PAC1-R coupled to AC 
correlates with reduced proliferation of cortical precursors (Nicot and DiCicco-
Bloom, 2001). 
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2.5. cAMP SIGNALING IN NEURONS 
 
 
Cyclic adenosine monophosphate (cAMP) is a widely used intracellular second 
messenger synthesized from ATP by the action of adenylate cyclase (AC). Adenylate 
cyclase is an enzyme bound to the inner face of the plasma membrane that trasduce a 
variety of extracellular signals acting through G protein-coupled receptors. Many 
substances utilize cAMP as second messenger, by binding to receptors coupled to AC 
through G proteins: hormones (e.g. glucagon), neurotransmitters (e.g. adrenalin), 
peptides (e.g. PACAP) and prostaglandins. Main target of cAMP in all cells is protein 
kinase A (PKA). PKA is a tetramer composed of two regulatory and two catalytic 
subunits. Binding of cAMP to PKA regulatory subunit releases the catalytic subunit 
that can then phosphorylate target proteins in the cytoplasm and nucleus. In 
eukaryotes gene transcription in response to cAMP elevation is mediated by  
transcription factors of the leucine-zipper family. Genes under the control of cAMP 
contains in their promoter region a cAMP response element (CRE), a palindrome 
sequence of 8 bp (TGACGTCA) that is recognized by cAMP responsive element-
binding protein (CREB) and related proteins. CREB is a 43 kD leucine-zipper 
transcription factor that is activated by phosphorylation on a serine residue (Ser133). 
CREB can be phosphorylated by PKA, thus linking cAMP signaling to gene 
transcription. Besides CREB can also be phosphorylated by other kinase including 
calcium/calmoduline-dipendent kinase (CaMK) and PKC.  
In neurons and neuronal-like cell line (e.g. the neuroendocrine cell line PC12) cAMP 
signaling appears also to activate the extracellular-regulated kinase 1 and 2 (ERK1/2) 
cascade. Canonical ERK1/2 activation in response to growth factors (e.g. EGF or 
NGF) is achieved through activation of the small G protein Ras (retrovirus-associated 
DNA sequence) that in turn activates the kinase c-Raf that then phosphorylates the 
mitogen-activated kinasae 1 and 2 (MEK1/2) which finally phosphorylates ERK1/2. 
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In neurons and PC12 cells the MEK-ERK pathway is also activated by the action of 
cAMP. This pathway involves the PKA-dependent activation of the Ras-related small 
G protein Rap1 and the subsequent activation of B-Raf (a c-Raf isoform). Given that 
B-Raf is highly expressed in neuronal and neuroendocrine cells, this Rap1-dependent 
pathway may be unique to these types of cells (Grewal et al., 1999). This signalling 
pathway has been implicated in ERK1/2 activation by PACAP/cAMP signaling in 
cultured cerebellar granule cells (Obara et al., 2007). A key mediator of MEK-ERK 
cascade on gene transcription has been identified in the transcription factor Elk-1 (a 
member of the Ets family of transcription factors). Elk-1 is a substrate for ERK1/2 
and mediates the expression of immediate early genes involved in MEK-ERK 
cascade response (Marais et al., 1993; Vossler et al., 1997). Besides in cerebellar 
granule cells cAMP/PKA-dependent ERK1/2 activation leads to the expression of the 
inducible transcription factor c-Fos (Figure 2.4) (Vaudry et al., 1998). c-Fos 
expression can be induced by the action of a variety of transcription factors acting on 
regulatory region of the gene, including CREB and Elk-1 (Seternes et al., 1998). c-
Fos is part of a family of inducible transcription factors that also comprise FosB, Fra1 
and Fra2. This proteins are characterized by a leucin-zipper motif that mediates the 
heterodimerization with members of the Jun family (c-Jun, JunB e JunD) of 
transcription factors to form the AP1 (activator protein 1) complex. The AP1 
complex mediates the transcription of target genes by binding the palindromic 
sequence TGA(C/G)TCA. AP1 complex binding on this sequence can either activate 
or repress the expression of target gene depending on the subunit composition of the 
complex. It has been reported that AP1 complexes composed of Fos/Jun are mainly 
activator of transcription while Fos/JunB heterodimer are mainly repressor of 
transcription (Kovacs, 1998). 
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Figure 2.4. Schematic representation of pathway activated by cAMP 
signaling in neurons.
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3. EXPERIMENTAL PROCEDURES 
 
 
 
Plasmids. The following reporter plasmids were used for this study:  pRL-TK 
(Promega, Madison, WI), pTK-βgal, pTK-Luc (Ciani et al., 2002) in which the 
tymidine kinase (TK) promoter drives the expression of Renilla luciferase, β-
galactosidase and Firefly luciferase respectively; AP1-Luc, CRE-Luc, and NFκB-Luc 
(Ciani et al., 2002) and Lot1-Luc (Ciani et al., 2003) in which the expression of 
Firefly luciferase is driven by tandem repeats of consensus-binding sequence for 
AP1, CREB, NFκB and Lot1 transcription factors, respectively.  
The following expression plasmids bearing the cDNA of the indicated proteins were 
also used: pSV40-cFos, pCMV-cJun, and pCMV-Fra1 (these plasmids were a kind 
gift of Dr. G. Perini, University of Bologna, Bologna, Italy); pCI-JunB (a kind gift of 
Dr. D. Chalbos, INSERM U540, Montpellier, France); pCMV-A-Fos and pCMV-A-
CREB (a kind gift of Dr. C. Vinson, National Institutes of Health, Bethesda, MD).  
 
Cloning of the Rat Lot1 Promoter and Construction of the Luciferase Reporter 
Vectors. For luciferase reporter vector construction, the rat Lot1 promoter region 
from 2099 bases upstream of the Lot1 transcription start site (GenBankTM accession 
number U72620) to 2 bases downstream (from base 8682293 to base 8684394 of 
contig NW_043337) was cloned. by nested PCR. The target rat genomic region was 
amplified with primers Lot-F1 (5’-caaggaaagaaaaccacccc-3’) and Lot-R1 (5’-
aactcccgagcgttctcc-3’) for the first reaction and primers Lot-F1nex (5’-
cggatcctgggattacagatgctcataaa- 3’) and Lot-R1nex (5’-cgggatccgcgagtgaggctggagaa- 
3’) for the second (the BamHI sites used for cloning is underlined). The product was 
digested and cloned into the BAmHI site of BlueScript SK- plasmid (Stratagene, La 
Jolla, CA). The ~2.1-kb insert representing the putative Lot1 promoter was sub-
cloned upstream of the firefly luciferase gene into the pGL2-Basic vector (Promega) 
 46
with an EcoRV/SacI cut to generate the pGLot-2099 vector. Plasmids pGLot-1373, 
pGLot-515, and pGLot-327 were also generated by restriction endonuclease digestion 
of pGLot-2099. Mutation of the AP1 binding site at -268 bases from the transcription 
start site was introduced by PCR. The region upstream of the AP1 site (from -2099 to 
-269 bases) was amplified by PCR with primers Lot-F1nex and LotAPm (5’-
cggaattcttcggctgtctacgcacagc-3’), whereas the region downstream of the AP1 site 
(from -262 to +2 bases) was amplified by PCR with primers Lot-R1nex and LotAPv 
(5’-cggaattccgcagcgggtgcgtgg- 3’, the EcoRI sites used for cloning are underlined). 
The EcoRI site overlapping the AP1 site at -268 bp was used for cloning and to 
introduce the mutation. The two segments (digested with BamHI and EcoRI) were 
cloned into pBlueScript SK- to generate the full-length promoter bearing the mutation 
of the AP1 site at -268 bp (TGACTCA→GGAATTC). The mutated promoter was 
then subcloned into pGL2-Basic to generate vectors pGLot-2099APmut and pGLot-
327APmut. Finally, the region downstream of the AP1 site was sub-cloned in pGL2-
Basic to generate the pGLot-262 vector. All plasmids were sequenced with an ABI 
PRISM BigDye terminator cycle sequencing kit (Applied Biosystems, Foster City, 
CA) and run on an ABI PRISM 3730 DNA analyzer (Applied Biosystems).  
 
Cell Culture. All cells were kept in a 5% CO2 humidified atmosphere at 37 °C. 
Human embryonic kidney 293 (HEK293) cells were maintained in Dulbecco’s 
modified Eagle’s medium (DMEM) supplemented with 10% foetal bovine serum 
(Sigma, St. Louise, MO), 2 mM glutamine, 100 µg/ml penicillin, and 50 µg/ml 
streptomycin (Sigma). Primary cultures of CGC were prepared from the cerebella of 
7-day old Wistar rat pups as described previously (Gallo et al., 1982). Cells were 
plated on poly-D-lysine (20 µΜ; Sigma) coated dishes at a density of 2x103 
cells/mm2 and maintained in basal modified Eagle’s (BME) medium (Invitrogen, 
Carlsbad, CA) supplemented with 10% foetal bovine serum (Invitrogen), 25 mM 
KCl, 2 mM glutamine, and 0.05 mg/ml gentamycin (Sigma).  
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Treatments. Cells were stimulated with 10 µM forskolin (Sigma), 10 nM PACAP-38 
(Sigma) or 1 mM dibutyryl cAMP (Sigma) for the indicated times. The protein 
synthesis inhibitor cycloheximide (Sigma) was used at 10 µg/ml. The PI3-kinase 
inhibitor wortmannin (Calbiochem, La Jolla, CA) was used at 100 nM. The MEK1/2 
inhibitor U0126 (Calbiochem) was used at 10 µM. The ERK1/2 inhibitor KT5720 
(Calbiochem) was used at 10 µM (Davies et al., 2000). The specific PKA inhibitor 
H89 was used at 10 µM (Calbiochem) (Vaudry et al., 1998b). Cells were 
preincubated with inhibitors for 1 h before stimulation.  
 
Real-time Reverse Transcription-PCR. For quantification of Lot1 expression, total 
RNA was extracted from CGC with TriReagent (Sigma) according to the 
manufacturer’s instructions. Approximately 5 µg of RNA were digested with 10 units 
of RNase-free DNase (Promega) for 30 min at 37 °C. After DNase inactivation, RNA 
was retrotranscribed with an oligo(dT)12–18 primer (0.5 µM) and 200 units of 
Moloney murine leukemia virus (M-MLV) reverse transcriptase (Invitrogen) 
according to the manufacturer’s instructions. For real-time PCR, the following 
primers pairs were used: Lot1 (5’-ttagctcgtagttgcgtgtta-3’ sense and 5’-
cgggtccctgaaaagaacaca-3’ antisense); glyceraldehyde-3-phosphate dehydrogenase 
(GADPH) (5’-gaacatcatccctgcatcca-3’ sense and 5’-ccagtgagcttcccgttca-3’ antisense); 
c-Fos (5’-tggacctgtctggttccttc-3’ sense and 5’-atgcaccagctcagtcagtg-3’ antisense). 
Real-time PCR was performed using a SYBR Premix Ex Taq kit (Takara, Shiga, 
Japan) according to the manufacturer’s instructions in an iCycler iQ real-time PCR 
detection system (Bio-Rad, Hercules, CA). Fluorescence was determined at each 
cycle. Real-time PCR was done under the following universal conditions: 10 min at 
95 °C, 40 cycles of denaturation for 15 s at 95 °C, and annealing/extension for 30 s at 
60 °C. Relative quantification of target gene expression towards the housekeeping 
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gene GAPDH was performed according to the 2-∆∆Ct method (Livak and Schmittgen, 
2001) .  
 
Northern Blotting. The expression of Lot1 in CGC was determined by Northern 
blotting. Approximately 30 µg of total RNA was loaded per lane and fractionated on 
a formaldehyde-containing 1% agarose gel. Following transfer to Hybond-N 
membrane (Amersham Biosciences, Upsala, Sweden), Lot1 mRNA was detected 
using an α-32P-labeled full-length cDNA probe. Cyclophilin probes were used for 
quantification as described previously (Taubenfeld et al., 2001). Membranes were 
washed at a maximum stringency of 0.1X SSC and 0.1% SDS at 65 °C.   
 
Transfection. All cells were transfected with polyethyleneimine (25 kDa; Sigma) as 
described previously (Boussif et al., 1995; Pennuto et al., 2002). For luciferase 
assays, HEK293 cells were plated 24 h before transfection in 24-well plates (105 
cells/well). Cells were transfected with 1–2 µg of plasmid DNA as indicated for 3 h 
in DMEM. The pTK-βgal reporter plasmid was cotransfected together with the Lot1-
luciferase reporter vectors to normalize for transfection efficiency. For luciferase 
assays, CGC were plated in poly-D-lysine-coated 24-well plates (5x105 cells/well) 
and transfected after 24 h with 1.05–1.55 µg of plasmid DNA as indicated for 2 h in 
complete medium. CGC were cotransfected with the pRL-TK reporter plasmid 
together with Lot1-luciferase reporter vectors at 1:20 ratio to normalize for 
transfection efficiency.  
 
Luciferase Assay. Luciferase activity in CGC was measured 48 h after transfection 
using a Dual-Luciferase assay kit (Promega) according to the manufacturer’s 
instructions on a TD-20/20 luminometer (Promega). Firefly luciferase activity was 
normalized for each sample by dividing by the Renilla luciferase activity in the same 
sample. Luciferase activity in HEK293 cells was measured as described previously 
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(de Wet et al., 1987) and normalized for β-galactosidase activity in the same sample 
(see below).  
 
β-galactosidase Assay. β-galactosidase activity was measured as described previously 
(Ciani and Paulsen, 1995). In brief, 20 µl of HEK293 lysate was added to 100 µl of 
β-galactosidase assay buffer (60 mM Na2HPO4, 40 mM NaH2PO4, 10 mM KCl, 1 
mM MgCl2, and 0.34% β-mercaptoethanol, pH 7.5) containing 4 mg/ml o-
nitrophenyl-β-D-galactopyranoside (ONPG) (Sigma) and incubated for 1 h at 37 °C. 
The reaction was stopped with 50 µl of 1 M Na2CO3, and the absorbance at 420 nm 
was measured using a Benchmark multiplate reader (Bio-Rad).  
 
Western Blotting. The following antibodies were used: anti-phosphorylated ERK1/2 
and anti-phosphorylated MEK1/2 polyclonal antibodies (1:1000 dilution; Cell 
Signaling Technology, Beverly, MA); anti-phosphorylated cAMP-responsive 
element-binding protein (CREB) polyclonal antibody (1:2000 dilution; Upstate 
Biotechnology, Lake Placid, NY); anti-Lot1 polyclonal antibody (1:1000 dilution) 
(Ciani et al., 2003); anti-c-Fos and anti-c-Jun polyclonal antibodies (1:2000 dilution; 
Santa Cruz Biotechnology, Santa Cruz, CA); and anti-β-actin polyclonal antibody 
(1:2000 dilution; Sigma). For the preparation of total cell extracts, cells were lysed in 
lysis buffer (2% SDS, 10 mM dithiothreitol, 10 mM Tris-HCl, pH 8 and 1% protease 
and phosphatase inhibitors mixture (Sigma)). For the preparation of nuclear extracts, 
cells were lysed in low salt buffer (10 mM Hepes, 50 mM NaCl, 1 mM EDTA, 0.1% 
Nonidet P-40, 1 mM dithiothreitol, and 1 mM phenylmethylsulfonyl fluoride, pH 8) 
for 10 min at 4 °C. After centrifugation, nuclei were extracted with hypertonic salt 
buffer (20 mM Hepes, 420mM NaCl, 1 mM EDTA, 1 mM dithiothreitol, 10% 
glycerol, and 1 mM phenylmethylsulfonyl fluoride, pH 8). The protein concentration 
of samples was estimated by the Lowry method (Lowry et al., 1951). Equivalent 
amounts (50 µg) of protein were subjected to electrophoresis on an SDS-10% 
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polyacrylamide gel. The gel was then blotted onto a nitrocellulose membrane 
(Amersham Biosciences), and equal loading of protein in each lane was assessed by 
brief staining of the blot with 0.1% Ponceau S. Blotted membranes were blocked for 
1 h in 5% milk in Tris-buffered saline (10 mM Tris-HCl and 150 mM NaCl, pH 8.0) 
and 0.1% Tween-20 and incubated overnight at 4 °C with primary antibodies. 
Membranes were washed and incubated for 1 h at room temperature with HRP-
conjugated anti-rabbit antibody (1:1000 dilution; Amersham Biosciences). Specific 
reactions were revealed with the ECL Western blotting detection reagent (Amersham 
Biosciences).  
 
Immunofluorescence. For immunofluorescence studies, the following antibodies were 
used: monoclonal anti-NeuN antibody (Chemicon), anti-neural cell adhesion 
molecule (NCAM) and anti-glial fibrillary acidic protein (GFAP) antibodies (Sigma), 
anti-bromodeoxyuridine (BrdU) and FITC-conjugated anti-BrdU antibodies (Roche 
Applied Science, Mannheim, Germany), and anti-Lot1 polyclonal antibody (Ciani et 
al., 2003). Cells (plated on poly-D-lysine-coated coverslips) were fixed for 30 min in 
4% paraformaldehyde in 120 mM sodium phosphate buffer, pH 7.4, and then rinsed 
three times with phosphate-buffered saline (PBS). For BrdU immunofluorescence, 
coverslips were treated with 2 N HCl for 30 min and extensively washed with PBS. 
Coverslips were then incubated overnight at 4 °C with appropriate dilutions of the 
primary antibody in 1.5% goat serum and 0.1% Triton X-100 in PBS, pH 7.4. Cells 
were then incubated with Cy3-conjugated goat anti-mouse secondary antibody or 
with FITC-conjugated goat anti-rabbit secondary antibody (1:200 dilution; Sigma) for 
1–2 h at room temperature. After all incubations, specimens were extensively washed 
with PBS containing 0.1% Triton X-100. Coverslips were mounted on glass slides in 
PBS containing 70% glycerol and Hoechst 33342 (2 µg/ml). Confocal images were 
taken using a Leica TCS confocal microscope. Phase-contrast and fluorescence 
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images were taken using a Nikon Eclipse TE 2000-S microscope equipped with a 
Zeiss AxioCam MRm digital camera.  
 
Determination of the Labeling Index. CGC (plated on poly-D-lysine coated 
coverslips) were cultured for 18 h, treated with 10 µM bromodeoxyuridine (BrdU; a 
thymidine analogue that is incorporated in the DNA of proliferating cells during the S 
phase of the cell cycle) for an additional 6 h, fixed, and processed for BrdU 
immunofluorescence as described above. The corresponding phase-contrast and 
fluorescence images (taken from random microscopic fields, 10–12 for each 
coverslip) were superimposed and used to determine the labeling index), defined as 
the percent of BrdU-positive cells out of the total number of cells in three 
independent experiments performed in duplicate. Glial cells, which represent ~3-5% 
of the total cell number in CGC cultures (Ciani and Paulsen, 1995), were recognized 
on the basis of phase-contrast morphology and were excluded from scoring.  
 
Bioinformatics. Transcription factors binding site search on the rat Lot1 promoter was 
performed with MatInspector software (Quandt et al., 1994). Alignment of mouse and 
rat Lot1/Zac1 promoter sequences was performed with Clustal W software 
(Thompson et al., 1994). 
  
Statistics. Data are expressed as the means ± S.E., and statistical significance was 
assessed by Student t-test or one-way analysis of variance (ANOVA), followed by 
Bonferroni’s or Dunnett’s post hoc test, where appropriate. Differences were 
considered to be significant starting from p<0.05. Statistical analysis was performed 
using Prism 4.0 (GraphPad Software, San Diego, CA).  
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4. RESULTS 
 
 
4.1. PACAP AND FORSKOLIN UP-REGULATE Lot1 
EXPRESSION THROUGH cAMP  
 
As shown in Fig. 4.1, PACAP-38 treatment induced a large increase in Lot1 mRNA 
in differentiated CGC kept for 7 days in vitro (DIV). The effect of PACAP on Lot1 
induction was mimicked by the stable cAMP analogue dibutyryl-cAMP and by 
forskolin, a potent activator of adenylate cyclase. This clearly indicates the 
involvement of cAMP signaling cascade in the induction of Lot1 expression in 
response to PACAP.  
As it has been reported that Lot1 overexpression correlates with apoptotic cell death 
in other systems (Spengler et al., 1997), we tested whether Lot1 expression was 
affected by changing culture conditions to a well established paradigm of apoptosis 
induction in CGC: serum and potassium withdrawal (Contestabile, 2002). Shifting 
culture conditions to low potassium (5 mM) and serum-free medium did not alter 
Lot1 expression (Fig. 4.1 A), indicating that it is not involved in induction of 
apoptosis in CGC.  
To study the time course of cAMP-mediated Lot1 up-regulation in CGC, we used 
forskolin to maximally increase intracellular cAMP and examined the expression of 
Lot1 at the mRNA level. Northern blot analysis of CGC culture extracts demonstrated 
that induction of Lot1 mRNA was detectable by 30 min after exposure to forskolin, 
reached its maximum between 2.5 and 6 h, and remained elevated for at least 12 h 
(Fig. 4.1 B). By Western blot analysis using a specific anti-Lot1 antibody (Ciani et 
al., 2003), we found that induction of Lot1 expression by either PACAP or forskolin 
at the protein level reflected that observed at the mRNA level (Fig. 4.1, C and D).  
Co
nt
ro
l
Di
bu
tyr
yl-
cA
MP
 
Fo
rs
ko
lin
5 m
M 
KC
lA B
PA
CA
P-
38
- 30’   2.5h     6h      8h      12h
Forskolin
0.00
0.25
0.50
0.75
1.00
1.25
Control
PACAP-38
Forskolin
D
en
si
to
m
et
ry
Lo
t1
/A
ct
in
*
*C
on
tro
l
PA
CA
P-
38
Fo
rs
ko
lin
FIGURE 4.1. Effect of PACAP-38 and forskolin on Lot1 mRNA and 
protein expression in CGC. 
A) CGC at 7 DIV were stimulated with PACAP-38 (10 nM), dibutyryl-
cAMP (1mM), or forskolin (10 µM) for 12 h or shifted to 5mM KCl
serum-free medium for 6 h, and total RNA (20 µg) was analyzed by 
Northern blotting using a Lot1 cDNA probe. A representative Northern 
blot is shown. B) CGC at 7 DIV were stimulated with forskolin (10 µM) 
for 0.5, 2.5, 6, 8, or 12 h, and total RNA (20 µg) was analyzed by 
Northern blotting using a Lot1 cDNA probe. A representative Northern 
blot is shown. C) expression of Lot1 protein was assayed by Western 
blotting of nuclear extracts from CGC at 7 DIV that had been treated 
with PACAP-38 (10 nM) or forskolin (10 µM) for 24 h. D) Lot1 protein 
expression was quantified and normalized for β-actin. Error bars are the 
means ± S.E. of four experiments. *, p<0.01 compared with the control 
(Bonferroni’s test after ANOVA). 
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FIGURE 4.2. Cytological evaluation of Lot1 immunoreactivity in 
CGC. 
CGC cultures at 7 DIV were treated for 24 h, after which time cells 
were processed for immunocytochemistry. A–C) confocal images of 
doubly immunostained CGC for Lot1 (green) and NCAM (red). A) 
control; B) forskolin (10 µM); C) PACAP-38 (10 nM). Arrows indicate 
CGC nuclei strongly stained for Lot1. Bar 40 µm. D) confocal image of 
CGC treated with forskolin and doubly immunostained for Lot1 (green) 
and NeuN (red), arrows indicate double labeled cells (yellow). E) 
confocal image of CGC culture stimulated with forskolin and doubly 
immunostained for Lot1 (green) and GFAP (red). Arrows indicate 
Lot1-positive GFAP-negative cells; arrowhead points to a GFAP 
positive glial cell not expressing Lot1. Bar 20 µm. 
A B
Forskolin
W
or
tm
an
nin
KT
57
20
U0
12
6
- +        +         +        +
A
B
0
500
1000
1500
2000
2500
3000
Forskolin - +      +       +       +
KT5720 - - +       - -
H89                  - - - +       -
U0126              - - - - +
*
# #
#
%
 L
ot
1/
G
A
D
PH
0
500
1000
1500
2000
2500
3000
Forskolin - +         - +
Chx - - - +
*
#
%
 L
ot
1/
G
A
D
PH
C
FIGURE 4.3. Pharmacological 
dissection of pathways involved in 
Lot1 expression. 
A) CGC were treated with forskolin 
alone or in combination with 
wortmannin (100 nM), KT5720 (100 
nM), or U0126 (10 µM) for 12 h, and 
total RNA (20 µg) was analyzed by 
Northern blotting using a Lot1 cDNA 
probe. A representative Northern blot is 
shown. B) Lot1 mRNA expression was 
quantitatively measured by real-time 
reverse transcription-PCR of CGC that 
had been treated for 6 h with forskolin 
(10 µM) alone or in combination with 
KT5720 (100 nM), H89 (10 µM), or 
U0126 (10 µM). Data are expressed as 
the means ± S.E. of three independent 
experiments. *, p<0.001 compared with 
the control; #, p<0.001 compared with 
forskolin-stimulated samples 
(Bonferroni’s test after ANOVA). 
GAPDH, glyceraldehyde-3-phosphate 
dehydrogenase. C) the dependence of 
forskolin-induced Lot1 mRNA 
expression on protein synthesis was 
evaluated by realtime reverse 
transcription-PCR from CGC that had 
been treated for 6 h with forskolin (10 
µM) alone or in combination with the 
protein synthesis inhibitor 
cycloheximide (Chx; 10 µg/ml). Data 
are expressed as the means ± S.E. of 
three independent experiments. *, 
p<0.001 compared with the control; #, 
p<0.001 compared with forskolin-
stimulated samples (Bonferroni’s test 
after ANOVA).  
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As it was previously demonstrated that Lot1 is a nuclear protein (Spengler et al., 
1997), we used immunocytochemistry to verify its subcellular localization in CGC. 
Cultures at 7 DIV were treated with forskolin or PACAP-38 for 24 h; and thereafter, 
cells were fixed and processed for immunocytochemistry for Lot1 and the neuronal 
marker NCAM (neuronal cell adhesion molecule) as described under “Experimental 
Procedures”. The results showed that Lot1 was barely visible in the nuclei of 
untreated cells (Fig. 4.2 A), whereas forskolin (Fig. 4.2 B) and PACAP (Fig. 4.2 C) 
induced a generalized increase in Lot1 expression in the nuclei of granule cells. 
Notably the nuclei of some CGC exhibited a particularly strong up-regulation of 
nuclear protein expression (Fig. 4.2, B and C, arrows).  
CGC cultures are highly enriched in neurons but contain a 3-5% of glial cells (Ciani 
and Paulsen, 1995); in order to clearly identify cell type expressing Lot1 we 
performed a double immunostaining for Lot1 and a cell-specific marker for neuronal 
or glial cells (NeuN or GFAP respectively). 
Confocal microscopic observation of doubly immunostained cultures showed that 
Lot1 immunoreactivity was localized in nuclei of granule cells that were also positive 
for the antibody against the neuronal marker NeuN (Fig. 4.2 D, arrows), but not in 
nuclei of astrocytes labeled by the glial marker GFAP (Fig. 4.2 E, arrowhead).  
To explore the signaling cascades involved in Lot1 gene expression, we examined the 
effect of inhibitors of various protein kinases known to be activated in response to the 
forskolin-induced cAMP increase. We found that induction of Lot1 mRNA caused by 
exposure to forskolin was strongly counteracted by co-treatment with the PKA 
inhibitor H89, the MEK1/2 inhibitor U0126, or ERK1/2 inhibitor KT5720 (Fig. 4.3, 
A and B), but not by exposure to the PI3-kinase inhibitor wortmannin (Fig. 4.3 A), 
which is know to block, at the concentration used, Akt phosphorylation in response to 
insulin activation in CGC cultures (van Weeren et al., 1998). These finding indicates 
that cAMP-dependent Lot1 expression depends upon activation of PKA and MEK-
ERK signaling cascade.  
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In the presence of the protein synthesis inhibitor cycloheximide (Chx), forskolin-
dependent Lot1 induction was largely counteracted, implying the requirement of de 
novo protein synthesis for Lot1 mRNA induction in response to cAMP elevation (Fig. 
4.3. C).   
 
 
4.2. PACAP AND FORSKOLIN ACT AS ANTI-MITOGENIC 
STIMULI IN CGC 
 
To define the effects of cAMP elevation on CGC proliferation, we analyzed the 
incorporation of BrdU (a thymidine analogue which is incorporated in the DNA of 
proliferating cells during the S phase of the cell cycle) in cells exposed to PACAP or 
forskolin for 24 h after cell plating.  
We first performed a double labeling immunocytochemistry experiments for BrdU 
and the neuronal marker NCAM (Fig. 4.4 A) or BrdU and the glial marker GFAP 
(Fig. 4.4 B). This experiment demonstrated that most BrdU-positive cells were also 
labeled by NCAM, indicating that the dividing cells were, at this stage, mainly 
neuronal precursors.  
We next investigated the proliferative activity of cells expressing Lot1 in culture, by 
double immunocytochemistry experiments with anti-BrdU and anti-Lot1 antibodies. 
Microscopic observation of doubly immunostained cultures showed that Lot1 
immunoreactivity did not colocalize with proliferating BrdU-positive cells after 
forskolin treatment while cells showing strong Lot1 expression were found to be 
BrdU-negative (Fig. 4.4, C–E) indicating that the expression of this putative 
antiproliferative transcription factor negatively correlates with CGC mitotic activity.  
We verified the effect of intracellular cAMP increase on CGC proliferation by 
treating freshly plated cells with either PACAP or forskolin. Cell proloferation was 
evaluated by labeling cycling cells with BrdU. Calculating the labelling index (BrdU-
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FIGURE 4.4. Relationship between Lot1 expression and CGC 
proliferation.  
A) double immunofluorescence for NCAM (red) and BrdU (green). 
Arrow points to a BrdU/NCAM doubly labeled neuronal cells. B) double 
immunofluorescence for GFAP (red) and BrdU (green). Arrows indicate 
BrdU-positive GFAP-negative cells; arrowhead points to a GFAP-
positive BrdU-negative glial cell. Bars 20 µm. C–E) double 
immunofluorescence for Lot1 (red) and BrdU (green) of CGC at 1 DIV 
treated with forskolin (10 µM). C) Lot1 immunoreactivity; D) BrdU 
immunoreactivity; E) merged color image. Arrows indicate BrdU 
positive cells showing faint Lot1 expression; arrowheads point to BrdU-
negative cells strongly labeled for Lot1. Bar 25 µm. 
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Figure 4.5. Effect of PACAP-38 and forskolin on proliferation of CGC in culture.
A-C) freshly plated CGC cultures were stimulated (as indicated below) for 20 h. BrdU 
(10 µM) was added for the last 6 h, after which time cells were processed for 
immunofluorescence with anti-BrdU antibody (red). Final pictures were obtained by 
merging phase-contrast images with fluorescence images. A) control; B) forskolin (10 
µM); C) PACAP-38 (10 nM). Bar 50 µm. D) labeling index (LI) determination for CGC 
in culture. Four hours after plating, CGC were treated for 20 h with forskolin (10 µM), 
PACAP-38 (10 nM), H89 (10 µM), or U0126 (10 µM) as indicated, and exposed to BrdU 
(10 µM) for the last 6 h. Data are expressed as the means ± S.E. of three independent 
experiments in duplicate. *, p<0.01 compared with the control; #, p<0.05 compared with 
PACAP-treated samples; ##, p<0.01 compared with forskolin treated samples 
(Bonferroni’s test after ANOVA). E) Western blot analysis of Lot1 expression on nuclear 
extracts obtained from CGC at 1 DIV treated with forskolin (10 µM) for 24 h prior to 
analysis.
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labeled neurons/total neurons) based on direct counting of neurons identified by their 
morphology observed by phase-contrast microscopy, we found that exposure to 
forskolin or PACAP reduced the CGC proliferation rate, which was decreased by ~60 
or 70%, respectively, compared with untreated cells (Fig. 4.5, A-D). Moreover, we 
verified whether the PKA or MEK1/2 inhibitors, that blocked forskolin- or PACAP-
induced Lot1 up-regulation, also counteracted the proliferation rate reduction of CGC 
precursors. We found that the reduced CGC proliferation rate caused by exposure to 
forskolin or PACAP was significantly counteracted by co-treatment with H89 or 
U0126 (Fig. 4.5 D), whereas these two inhibitors had, by themselves, no effect on 
cell proliferation. Taken together, these results clearly correlate the anti-mitotic effect 
of cAMP signaling on CGC proliferation with Lot1 expression.  
 
 
4.3. FUNCTIONAL ANALYSIS OF THE Lot1 PROMOTER 
 
We cloned the 5’-flanking region of the Lot1 gene into the pGL2-Basic vector 
upstream of the Firefly luciferase gene to determine whether this region possesses 
transcriptional activity. The cloned rat Lot1 promoter region appears to be highly 
similar to the mouse Lot1 promoter (GenBankTM accession number AF314094) as 
observed by aligning the two sequences (Fig 4.6). To identify, within the Lot1 
promoter, the binding region responsible for the cAMP-induced Lot1 activation, 
serial deletions of the promoter were made. Complete or deleted constructs were 
transfected in CGC as described under “Experimental Procedures”, and cells were 
stimulated with forskolin for 24 h before luciferase measurements. The structures of 
the different constructs are schematically shown in Fig. 4.7 together with the results 
of experiments performed using the different plasmids. Insertion of the ~2.1-kb rat 
Lot1 genomic fragment (nucleotides -2099 to +2 with respect to the transcription start 
site of the Lot1 sequence in GenBankTM accession number U72620) into pGL2-Basic 
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vector (designated pGLot-2099) resulted in a high increase (up to ~30-fold) in 
luciferase activity compared to the empty pGL2-Basic vector in basal culture 
conditions. Strong increase in pGLot-2099 activity (up to~160-fold) was obtained 
after forskolin stimulation, confirming cAMP responsiveness of the promoter (Fig. 
4.7). Results from transfection studies based on different truncated constructs of Lot1 
promoter, indicated that the cAMP-dependent activation domain in the Lot1 promoter 
is localized in proximal region. Indeed, the transcriptional activity stimulated by 
forskolin was abolished following the 5’-truncation of the promoter at nucleotide -
262, as shown for the pGLot-262 plasmid, whereas other truncated constructs, in 
which the promoter was progressively deleted up to nucleotide -327, only marginally 
affected forskolin-induced transcriptional activity (Fig. 4.7). This indicates the 
requirement of the promoter region between -327 and -262 bp from the transcription 
start site, for cAMP-dependent Lot1 transcription. Software analysis with  
MatInspector (Quandt et al., 1994) was used to identify putative binding sites for 
transcription factors on Lot1 promoter. Within the region between -327 and -262 bp, 
that confers cAMP responsiveness to the promoter, an AP1 site (located at -268 bp 
and conserved in the mouse Lot1/Zac1 promoter; Fig. 4.6) was found. Accordingly, a 
reporter vector bearing the minimal promoter responsive to cAMP with a mutated 
form of this site (pGLot-327AP1mut) did not exhibit any significant response to 
forskolin stimulation (Fig. 4.7). A similar mutation in the complete construct (pGLot-
2099AP1mut) also dramatically decreased the effect of forskolin stimulation 
(compare with pGLot-2099 in figure 4.7). Besides, software analysis also identified 
additional potential binding site with partial homology to canonical binding 
sequences: two AP1-like binding site (at -1887 and -891) and a cAMP response 
element (CRE)-like binding site (at -1411). However this binding sites did not appear 
to be essential for cAMP-dependent Lot1 expression as their deletion in the truncated 
construct did not significantly affect Lot1 promoter activity. Despite this fact we can 
not exclude a minor role for this potential binding site in mediating Lot1 
transcriptional activation. Indeed a minor stimulating effect of forskolin over basal 
 
 
 
mLot1     TGCCCAGTTTCTGGTTTGCGATGTGGCCGAGG----GTGGATCATCTCTGTGGGGATGGA 
rLot1     CGCCCAGCCTCTGGTTTGCGATGTAGCCGAGGGAGGGTGGATCATCTCGTTGGCGATGGA 
           ******  *************** *******    ************  *** ****** 
 
mLot1     GGAATCAATATTCAACGCAGATTTTCAGACTGAGTTGAGGCTACCTGCGCCAACGCGGCA 
rLot1     GCGATCAATACTACACGCAGATATTCGGGCAGACTCGAGGCTACCTGCGCCAACGCGGCA 
          *  ******* *  ******** *** * * ** * ************************ 
 
mLot1     CCTAGGAGACCTTGGCTTTGCGCATACAGCCGATGAGTCACCGCTGGG--CTGCGTGGCT 
rLot1     CCTAGGCGACCTTGGCTGTGCGTAGACAGCCGATGAGTCACCGCAGCGGGCTGCGTGGCT 
          ****** ********** **** * ******************* * *  ********** 
 
mLot1     GTCCTCCCCCACCGACCCCCGGAGCCCCAACGGGGCCTCCTCCTCACACGTGACACTG-- 
rLot1     GTCCTCCCCCGCCGACCCCCG-AGCCCCAACGGGGCCTCCTCATCCCACGTGACATCGGA 
          ********** ********** ******************** ** *********  *   
 
mLot1     --GAGGGGGGGGGAGCAGCTCCTCTCGGGCTGCCCCGCCCGCAGCCTCGTCCATGCAGCC 
rLot1     ATGGGGGGGGGGGAGCAGCTCCTCTCG--CAGCCCCGCCCGCAGCCTCGTCCGTGCAGCC 
            * ***********************  * ********************* ******* 
 
mLot1     ATCCCCTTGGCTGGCGTGTTGCGCGGCAAAGCCCACGGCATCTGCGATTTGTCACTCAGC 
rLot1     ATCCCCTTGGCTGGCTTGTTGCGCGGCAAAGCCCACGGCGTCTGTGATTTGTCACTCGGC 
          *************** *********************** **** ************ ** 
 
mLot1     TTGGGCTGGGACCGCCCCGAGCCTTGATTTAGCCGGG--GCTGGGGCGTTCTCCAACCTC 
rLot1     TCGGGCAGGGACCGCCCCGAGCCTTGATTTAGACGGGGTCCGGGGGCGTTCTCCAGCCTC 
          * **** ************************* ****   * ************* **** 
               
mLot1     ACTCGCCTGGCAGGCGGGAGAACGCTCGGGGAGTTGCGGCCGCGGGCACCGGGCTCGCGG 
rLot1     ACTCGCCTGGCAGGCGGGAGAACGCTCGGG-AGTTGTGGCCGTGGGCACGGGGCTCGCGG 
          ****************************** ***** ***** ****** ********** 
 
FIGURE 4.6. Rat and mouse Lot1 promoters are highly conserved.
Sequence alignment of Lot1/Zac1 proximal promoter region for mouse 
(mLot1; AF314094) and rat (rLot1; NW_043337 ) according to Clustal
method. The figure shows the alignment of the proximal portions of the 
promoters ( ~420 bp upstream of the transcription start site). Results 
indicate an high degree of similarity between the two sequence (89.5% 
identity in the region shown). Asterisks indicate conserved nucleotide, 
the arrow indicates the transcription start site, while in red is outlined the 
AP1 binding site, located at -268 bp from the transcription start site 
(rLot1 numeration), which is conserved in rat and mouse sequences.  
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FIGURE 4.7. The Lot1 promoter is activated by forskolin through an AP1-responsive 
element. Upper, schematic representation of the cloned Lot1 promoter region (not drawn to 
scale). The AP1 response elements and CRE found by software analysis are indicated. Lower left, 
schematic representation of the reporter plasmids used in these experiments. The plasmids 
contained a progressively shorter fragment of the Lot1 promoter or Lot1 promoter site mutants 
driving the expression of the luciferase gene. Lower right, luciferase reporter analysis of the Lot1 
promoter. One day after plating, CGC were transfected with 1 µg of the indicated Lot1-luciferase 
(Luc) reporter plasmids and 0.05 µg of Renilla luciferase reporter plasmid (pRL-TK) to normalize 
for transfection efficiency. Twenty-four hours after transfection, cells were incubated with (black 
bars) or without (white bars) 10 µM forskolin for an additional 24 h. The results are given as fold
increase over pGL2-Basic activity and are the means ± S.E. of four to five experiments done in 
triplicate. Data were analyzed with Bonferroni’s test after ANOVA. **, p<0.001, and *, p<0.01, 
difference in the forskolin-stimulated versus basal conditions for the same vector; ##, p<0.01, and 
#, p<0.05, difference in the basal versus pGLot-2099 basal conditions; °, p<0.05, difference in the 
forskolin-stimulated versus pGLot-2099 stimulated conditions. A post hoc t-test confirmed the 
results from Bonferroni’s test and additionally revealed a difference between pGLot-
2099AP1mut-stimulated versus basal conditions. §, p<0.05 (t-test). 
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conditions was noticed with the pGLot-2099AP1mut construct, possibly due to the 
presence in the long upstream genomic fragment of forskolin-responsive site(s) with 
lesser effect on transcription. Nevertheless our results clearly demonstrate that full 
activation of Lot1 expression by forskolin requires the intact AP1 site at -268 bp. 
Accordingly, a construct in which luciferase expression was driven by tandem repeats 
of AP1 consensus motifs (AP1-Luc) (Fig. 4.7), used as control for the AP1-dependent 
transcriptional activity induced by forskolin, exhibited strong activation when 
transfected in CGC. Moreover, these experiments revealed that the promoter activity 
of the constructs deleted or mutated in the AP1 site (pGLot-262, pGLot-2099APmut, 
and pGLot-327APmut) caused a decrease in basal transcription, suggesting that this 
site is also important for unstimulated basal transcription (Fig. 4.7).  
 
 
4.4. INDUCTION OF Lot1 TRANSCRIPTIONAL ACTIVITY AND 
c-Fos EXPRESSION BY FORSKOLIN IN CGC. 
 
To study in further detail the mechanism of cAMP mediated induction of Lot1 
transcriptional activity, reporter gene assays were performed using plasmids 
containing a tandem repeat of Lot1, CREB, AP1, or NF-κB consensus response 
elements placed upstream of a Firefly luciferase cDNA (Lot1-Luc, CRE-Luc, AP1-
Luc, and NFκB-Luc) or a control plasmid in which the expression of the Firefly 
luciferase is driven by the thymidine kinase promoter (TK-Luc). Twelve hours after 
transfection with the reporter plasmids, cells were cultured for an additional 24 h in 
the presence or absence of forskolin. Although no changes in luciferase activity were 
observed upon forskolin treatment in NFκB-Luc- or TK-Luc-transfected cells, this 
treatment remarkably induced the transcriptional activity of Lot1-Luc (~5-fold), 
CRE-Luc (~25- fold), and AP1-Luc (~3.5-fold) (Fig. 4.8), thus showing that, besides 
CREB and AP1 transcriptional activity, also Lot1 transcriptional activity was induced 
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by forskolin in CGC. As shown in Fig. 4.3 B, inhibition of the MEK-ERK cascade by 
the MEK inhibitor U0126 or of the PKA cascade by the PKA inhibitor H89 abrogated 
Lot1 induction by forskolin, implying that forskolin induces Lot1 expression through 
activation of these pathways. In agreement with this conclusion, exposure of CGC to 
forskolin caused a rapid (30 min) and long lasting (3 h) phosphorylation of MEK1/2 
and ERK1/2 (Fig. 4.9 A). The MEK-ERK signaling pathway regulates the activity of 
AP1 sites by increasing both the synthesis and activation of the ligands of this 
binding site, the immediate-early genes c-Fos and c-Jun (Raingeaud et al., 1996). The 
protooncogene c-Fos is known to play a key role in the control of cell proliferation 
and differentiation and programmed cell death (Didier et al., 1992; Holt et al., 1986; 
Muller and Wagner, 1984; Ruther et al., 1987) and to be induced by PACAP in CGC 
(Vaudry et al., 1998b). We therefore examined the kinetics of expression of c-Fos as 
well as c-Jun in CGC after forskolin treatment. As shown in Fig. 4.9 A, forskolin 
induced c-Fos protein expression, which peaked 3 h after forskolin stimulation, while 
c-Jun appeared to be constitutively expressed. Inhibition of PKA by H89 prevented 
forskolin-induced MEK1/2 phosphorylation, with a consequent decrease in ERK1/2 
and CREB phosphorylation (Fig. 4.9 A), and c-Fos induction (Fig. 4.9, A-C). These 
results demonstrate that PKA is required for forskolin-induced transcription of c-Fos 
in CGC. Forskolin-induced c-Fos expression at both the protein and mRNA levels 
was also significantly decreased by directly interfering with the MEK-ERK pathway 
through the specific MEK1/2 inhibitor U0126 (Fig. 4.9, A–C) indicating the 
requirement of this pathway activation for full achievement of c-Fos expression.  
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FIGURE 4.8. Analysis of pathways activated by cAMP in CGC. 
CGC were transfected with 1 µg of reporter plasmids containing tandem 
repeats of Lot1, CREB, AP1, or NF-κB consensus response elements as 
indicated. CGC were cultured for 24 h and treated with forskolin (10 
µM) for an additional 24 h, and then luciferase activity was measured. 
Error bars are the means ± S.E. of three experiments. *, p<0.01 versus 
unstimulated conditions (Bonferroni’s test after ANOVA). 
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FIGURE 4. 9. Analysis of 
pathways involved in cAMP-
dependent Lot1 expression
A) shown are the results of Western 
blot analysis of MEK, ERK, and 
CREB phosphorylation (P) and c-
Fos and c-Jun expression in CGC. 
Cells were treated for the indicated 
times with forskolin alone or with 
the MEK inhibitor U0126 (10 µM) 
or the PKA inhibitor H89 (10 µM). 
B) c-Fos protein expression was 
quantified and normalized for β-
actin. Error bars are the means ± 
S.E. of three experiments. *, p<0.05 
compared with the control; **, 
p<0.01 compared with the control; 
#, p<0.05 compared with the 
corresponding forskolin-treated 
samples; ##, p<0.01 compared with 
the corresponding forskolin-treated 
samples (Bonferroni’s test after 
ANOVA). C) c-Fos mRNA 
expression was quantitatively 
measured by real-time reverse 
transcription-PCR in CGC treated 
with forskolin (10 µM), U0126 (10 
µM), or H89 (10 µM). Data are 
expressed as the means ± S.E. of 
two independent experiments. *, 
p<0.001 compared with the control; 
#, p<0.05 compared with forskolin-
stimulated conditions; ##, p<0.001 
compared with forskolin-stimulated 
conditions (Bonferroni’s test after 
ANOVA). GAPDH, 
glyceraldehyde-3- phosphate 
dehydrogenase. 
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4.5. Lot1 EXPRESSION DOES NOT DEPEND ON cAMP-
INDUCED AP1 TRANSCRIPTION IN HEK293 CELLS 
 
We examined the promoter activity of Lot1 in a non-neuronal cell model, HEK293 
cell line. Transfection of these cells with the Lot1 reporter vector pGLot-2099 
resulted in remarkable levels of luciferase activity. However, the transcriptional 
activity was slightly decreased by forskolin stimulation in these cells. Besides, 
deletion of the 5’ distal most region of the promoter at nucleotide -1373 from the 
transcription start site resulted in a strong reduction of Lot1 promoter activity. This 
indicates that the AP1 site located at -268 bp is not essential for Lot1 transcription in 
this cells that in turns appear to depend upon the presence of the region upstream of 
nucleotide -1373 (Fig. 4.10 A). Accordingly Western blot analysis of Lot1 protein 
expression on HEK293 nuclear extracts showed a very low level of expression that 
was not increased by forskolin treatment (Fig. 4.10 insert). Furthermore, c-Fos 
expression in HEK293 cells was not stimulated but was actually depressed by 
forskolin, whereas the MEK-ERK cascade was only slowly and moderately activated 
(Fig. 4.10 B). To study in further detail Lot1 transcriptional activity in HEK293 cells, 
reporter gene assays were performed using the AP1-Luc or CRE-Luc reporter 
plasmid. Although forskolin treatment remarkably induced the transcriptional activity 
of CRE-Luc, no change in luciferase activity was observed in AP1-Luc transfected 
cells, thus confirming that AP1 transcriptional activity was not induced by forskolin 
in HEK293 cells (Fig. 4.10 C). Taken together, these results converge in 
demonstrating the lack of effect of cAMP on Lot1 expression in HEK293 cells.  
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4.6. c-Fos/c-Jun FAMILY PROTEINS CONTROL Lot1 
PROMOTER ACTIVITY 
 
To determine the mechanisms leading to AP1 site activation on the Lot1 promoter in 
CGC, we examined the transcriptional effects of c-Fos and c-Jun family members in 
transient transfection assays. We transfected CGC with wild type expression plasmid 
for c-Fos, Fra1, c-Jun, JunB proteins or a dominant-negative mutant of c-Fos (named 
A-Fos) (Olive et al., 1997) together with the reporter vector bearing the minimal Lot1 
promoter region responsive to cAMP elevation (pGLot-327), and cells were then 
stimulated or not with forskolin (Fig. 4.11 A). We found that only concomitant c-
Fos/c-Jun overexpression significantly increased pGLot-327 promoter activity under 
basal and forskolin-stimulated conditions (Fig. 4.11 A). All other conditions tested 
(overexpression of c-Fos, Fra1, c-Jun, JunB, c-Fos/JunB, or c-Jun/JunB) failed to 
induce any significant increase in pGLot-327 activity. On the other hand, 
overexpression of dominant-negative A-Fos significantly decreased pGLot-327 
activity upon forskolin treatment. We were next interested in determining whether 
enforced overexpression of c-Fos and c-Jun would activate the Lot1 promoter at the 
level of the AP1 site. To perform these experiments we cotransfected Lot1-luciferase 
reporter plasmids (pGLot-2099, pGLot-2099AP1mut, pGLot-327, pGLot-
327AP1mut, or pGLot-262) together with the c-Fos and c-Jun expression plasmids in 
CGC. Fig. 4.11 B shows that overexpression of c-Fos and c-Jun approximately 
doubled Lot1 transcription only when the Lot1-luciferase reporter plasmids contained 
the intact AP1 site (pGLot-2099 and pGLot-327). Furthermore, c-Fos/c-Jun 
overexpression no longer stimulated reporter gene activity when the AP1 site was 
selectively mutated (Fig. 4.11 B). These results indicate that Lot1 up-regulation 
elicited by cAMP elevation relies upon AP1-mediated transcriptional activity and that 
the composition of the heterodimer that binds at the AP1 site on the Lot1 promoter is 
likely c-Fos/c-Jun. We also tested whether c-Fos/c-Jun overexpression activates Lot1 
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FIGURE 4.10. Lot1 promoter activity in HEK293 cells. 
A) shown are the results from luciferase reporter analysis of the Lot1 promoter. HEK293 cells 
were transfected with 0.5 µg of the indicated Lot1-luciferase reporter plasmids and 0.5 µg of the 
β-galactosidase reporter plasmid (pTK-βgal) to normalize for transfection efficiency. After 
transfection, cells were incubated with (black bars) or without (white bars) 10 µM forskolin for 
24 h prior to luciferase measurement. Error bars are the means ± S.E. of three experiments. *, 
p<0.01 versus pGLot-2099 under basal conditions; #, p< 0.01 versus pGLot-2099 under 
forskolin-stimulated conditions (Bonferroni’s test after ANOVA). Insert show Lot1 protein 
expression in HEK293 nuclear extracts. Expression of Lot1 appear to be extremely low and not 
influenced by forskolin treatment in this cells.  B) Western blot analysis of ERK phosphorylation 
(P) and c-Fos and c-Jun expression in HEK293 cells. Cells were treated for the indicated times 
with forskolin (10 µM) alone or with the MEK inhibitor U0126 (10 µM). C) HEK293 cells were 
transfected with 0.5 µg of reporter plasmids containing tandem repeats of CREB (CRE-Luc) or 
AP (AP1-Luc) consensus response elements as indicated and 0.5 µg of the β-galactosidase
reporter plasmid (pTK-βgal) to normalize for transfection efficiency. After transfection, cells 
were incubated with (black bars) or without (white bars) forskolin (10 µM) for 24 h prior to 
luciferase measurement. Error bars are the means ± S.E. of three experiments. *, p<0.01 versus 
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FIGURE 4.11. The c-Fos/c-Jun heterodimer is responsible for cAMP-mediated Lot1 
transcriptional activity. 
A) CGC were cotransfected with 0.5 µg of the pGLot-327 reporter plasmid without 
(Control) or with 0.5 µg of the indicated expression vector for AP1 family proteins in the 
presence of 0.05 µg of pRL-TK. DNA quantity for each transfection was equalized with 
empty vector pcDNA3. Twenty-four hours after transfection, cells were incubated with 
(black bars) or without (white bars) 10 µM forskolin for an additional 24 h. The results are 
expressed as percent induction over control conditions and are the means ± S.E. of three to 
four experiments done in triplicate. *, p< 0.01 versus control conditions; **, p<0.001 
versus control conditions; #, p<0.05 versus control conditions (Dunnett’s test after 
ANOVA). B) shown is the specificity of c-Fos and c-Jun binding to the AP1 element 
involved in Lot1 promoter activation. CGC were cotransfected with 0.5 µg of the indicated 
Lot1-luciferase reporter plasmids without (control) or with 0.5 µg of c-Fos and c-Jun 
expression plasmids in the presence of 0.05 µg of pRL-TK. DNA quantity for each 
transfection was equalized with empty vector pcDNA3. HEK293 cells were cotransfected
with 0.5 µg the indicated Lot1-luciferase reporter plasmids without (control) or with 0.5 
µg of c-Fos and c-Jun expression plasmids in the presence of 0.5 µg of pTK-βgal. DNA 
quantity for each transfection was equalized with empty vector pcDNA3. The results are 
given as percent induction over control conditions and are the means ± S.E. of three to 
four experiments done in triplicate. *, p<0.01 versus pGLot-2099APmut, pGLot-
327APmut, and pGLot-262 (Dunnett’s test after ANOVA).
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FIGURE 4.12. CREB is not involved in cAMP-dependent activation 
of Lot1 promoter. 
CGC were cotransfected with 0.75 µg of pGLot-2099, pGLot-327 
reporter plasmids or a vector containing tandem repeats of CREB (CRE-
Luc) consensus response elements, without (Control) or with 0.75 µg of 
the expression vector for dominant-negative A-CREB in the presence of 
0.05 µg of pRL-TK to normalize for transfection efficency. DNA 
quantity for each transfection was equalized with empty vector pcDNA3. 
Twenty-four hours after transfection, cells were incubated 10 µM
forskolin for an additional 24 h. The results are given as the percent over 
basal control conditions and are the means ± S.E. of three experiments 
done in triplicate. *, p<0.01 versus control conditions (Dunnett’s test 
after ANOVA). 
 61
in HEK293 cells, in which cAMP does not induce c-Fos and Lot1 expression. These 
experiments revealed that the effect of overexpression of c-Fos/c-Jun on Lot1 
transcription in HEK293 cells was similar to that observed in CGC (Fig. 4.11 B). We 
have shown before that, in CGC, treatments that increased cAMP levels promoted 
CREB phosphorylation (Fig. 4.9 A). To test whether CREB may be a primary factor 
in controlling cAMP-dependent Lot1 transcriptional activation, we performed 
cotransfections with the full-length Lot1-luciferase reporter plasmid pGLot-2099 or 
the truncated pGLot-327, which lacks any obvious cAMP response element (CRE) 
binding site, and the dominant-negative mutant A-CREB (Ahn et al., 1998). Results 
indicate that, first of all, the Lot1 promoter constructs possessing (pGLot-2099) or not 
(pGLot-327) a CRE binding site were stimulated by forskolin in a similar manner, 
thus suggesting that CREB is not necessary for Lot1 activation (Fig. 4.12). Under our 
experimental conditions and in the presence of very strong activation of endogenous 
CREB by forskolin (see Fig. 4.9 A), the dominant-negative mutant A-CREB did not 
significantly inhibit forskolin-induced Lot1 transcription in both constructs (Fig. 
4.12). As a positive control, a plasmid containing tandem repeats of CREB (CRE-
Luc) consensus response elements was used. The results shown in Fig. 4.12 
demonstrate that, in this control plasmid, A-CREB was able to strongly inhibit both 
basal and forskolin-induced CRE-Luc activation.  
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5. DISCUSSION 
 
 
In this study, we have shown, at both the mRNA and protein levels, that expression of 
the growth suppressor gene Lot1 is up-regulated in CGC culture after elevation of 
cAMP intracellular concentration by either PACAP-38, forskolin or dibutyryl-cAMP 
treatments. Stimulation of the PACAP/cAMP signaling cascade was in parallel able 
to reduce proliferation of CGC in culture. Physiologically, cAMP-dependent Lot1 
induction parallels the negative regulation of CGC precursor proliferation mediated 
by cAMP, as we never observed its induction in dividing (BrdU-positive) cells. 
Furthermore, Lot1 induction was not related to apoptotic elimination of mature CGC 
whose survival was challenged by shifting them to non-depolarizing conditions and 
serum deprivation. These results implicate Lot1 as one of the elements in the cascade 
of molecular events triggered by PACAP/cAMP and suggest a role for Lot1 as 
mediator of the antiproliferative activity of PACAP.  
We have also analyzed the intracellular mechanisms involved in cAMP-dependent 
Lot1 expression by pharmacological dissection of the pathway with specific protein 
kinases and protein synthesis inhibitors. We have found that, in CGC, cAMP-
dependent Lot1 stimulation requires activation of PKA and MEK-ERK pathways 
activation as well as de novo protein synthesis of the immediate early gene c-Fos. We 
have identified a putative promoter region within 2.1 kb 5’-upstream of the Lot1 
transcription start site, and we have characterized a regulatory element that is 
involved in neuronal expression of the rat Lot1 gene after cAMP stimulation. We 
have provided evidence that the transcription of this gene depends upon an AP1 
binding site in the proximal promoter regulatory region (268 bp 5’-upstream of the 
transcription start site) through the binding of the c-Fos/c-Jun heterodimer.  
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The cAMP-dependent effects elicited by the exogenous adenylate cyclase activator 
forskolin were also replicated by the physiological neurotrophic factor PACAP, 
which we have demonstrated here to down-regulate neuronal precursor proliferation 
in parallel with induction of Lot1 expression. PACAP and its receptors are present in 
the developing nervous system (Basille et al., 1993; Gonzalez et al., 1997; Lioudyno 
et al., 1998; Masuo et al., 1992). PACAP belongs to a peptide family that includes 
secretin, glucagon, growth hormone releasing factor, and vasoactive intestinal peptide 
and interacts with target cells via G-protein-coupled receptors (Vaudry et al., 2000a). 
Cerebellar granule neurons express PACAP and its receptors during early 
neurogenesis in vivo while the peptide elicits survival and differentiation response in 
culture (Basille et al., 1995; Basille et al., 1993; Favit et al., 1995; Gonzalez et al., 
1997; Tabuchi et al., 2001). Notably, a high density of PACAP receptors linked to 
adenylate cyclase activation was found in the external granular layer of the 
developing cerebellum (Basille et al., 1993; Masuo et al., 1994), with a time window 
temporally matching Lot1 expression in the same layer (Ciani et al., 2003). 
Activation of the PAC1 receptors by PACAP has been shown to stimulate adenylate 
cyclase and phospholipase C activities in CGC, leading to activation of PKA and 
PKC (Basille et al., 1995; Favit et al., 1995). The signal transduction pathways that 
mediate the anti-apoptotic effect of PACAP in cerebellar granule neurons have been 
investigated in several experimental models. While the cAMP-PKA pathway has 
been clearly implicated in PACAP survival response (Chang et al., 1996; Kienlen 
Campard et al., 1997; Vaudry et al., 1999; Vaudry et al., 1998), the activation of 
phospolipase C and PKC does not seems to be involved (Vaudry et al., 1998; Vaudry 
et al., 2000b). The MEK-ERK pathway is a major signaling pathway in neural cells 
that is activated by PKA in CGC (Obara et al., 2007). Besides a it has been shown 
that inhibition of activation of the PKA-dependent MEK-ERK pathway abolishes the 
protective effect of PACAP on rat CGC (Villalba et al., 1997). Therefore, in addition 
to neurogenesis, PACAP signaling through PKA-MEK-ERK pathway is important 
for neuroprotection. Here, we have demonstrated that PACAP increases Lot1 gene 
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expression in cultured rat cerebellar neurons, thus suggesting the involvement of Lot1 
in the PACAP-mediated survival- and differentiation-promoting action in 
neurodevelopment. This relationship is supported by studies demonstrating 
neurotrophic interactions between Lot1/Zac1 and PACAP (Rodriguez-Henche et al., 
2002) as well as by available reports on Lot1/Zac1 expression in some brain areas 
during development (Ciani et al., 2003; Valente and Auladell, 2001).  
It is also important to note that, in this study, increased Lot1 expression induced by 
PACAP as well as by forskolin clearly did not compromise cell viability, as no signs 
of apoptosis could be detected in Lot1-positive neurons. Recent findings in animal 
models of excitotoxic injuries go in the same direction by linking Lot1 expression to 
neuroprotection and brain plasticity (Gillardon et al., 1998; Valente and Auladell, 
2001; Valente et al., 2004). Interestingly, in these models, a relationship between 
Lot1 expression and PACAP (Gillardon et al., 1998) or c-Fos (Valente et al., 2004) 
was suggested, similar to what we have demonstrated in this study. This functional 
relationship is likely essential for the physiological role of Lot1.  
The role of cAMP in the maturation of newborn neurons is well accepted (Fujioka et 
al., 2004; Nicot et al., 2002), and both PKA-dependent and PKA-independent 
pathways have been implicated in cAMP-mediated effects. Our study has shown that, 
in CGC, cAMP activation of Lot1 is PKA- and MEK-ERK-dependent, as it was 
counteracted by specific pathway inhibitors. Notably, the PKA-dependent mechanism 
implicated in Lot1 activation did not act through the CRE binding site present in the 
gene promoter. Indeed, deletion of the CRE-binding site on the cloned promoter did 
not abrogate on Lot1 activation after forskolin stimulation. Besides CREB, previous 
studies have shown that the cAMP-PKA pathway also activates the MEK-ERK 
signaling cascade in CGC trough the recruitment of Rap1 and subsequent B-Raf 
activation (Obara et al., 2007). Our data imply that forskolin-induced Lot1 
transcription in CGC is mediated by the PKA and MEK-ERK pathways. In many 
neuronal cells, increased cAMP can induce neuronal differentiation through 
activation of the mitogen-activated protein kinase cascade (Dugan et al., 1999; 
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Vossler et al., 1997). We have shown that inhibition of PKA completely blocked 
MEK1/2 first and consequently ERK1/2 activation by forskolin, demonstrating 
dependence of ERK1/2 activation by PKA. Moreover, blockade of forskolin-induced 
MEK1/2 activity with a selective inhibitor (U0126) not only reduced the magnitude 
and duration of ERK1/2 phosphorylation, but also blocked transcriptional activation 
of the Lot1 gene. These results provide clear evidence that ERK activation is 
absolutely required for transcriptional activation of the Lot1 gene. Interestingly, 
prolonged ERK1/2 activation in some cell types leads to the expression of a 
differentiated phenotype such as neurite outgrowth in PC12 cells (Marshall, 1995; 
Traverse et al., 1992). One of the targets of activated MEK-ERK pathway in 
mammalian cells is the transcription factor AP1, which is composed of members of 
the c-Fos and c-Jun family of DNA-binding proteins (Angel and Karin, 1991; Karin, 
1995). The MEK-ERK signaling pathways regulate AP1 activity in several ways, 
including increased synthesis and/or activation of c-Fos (Raingeaud et al., 1996). Our 
present results clearly suggest a link between the PKA-MEK-ERK pathways and c-
Fos activity in the regulation of Lot1 expression through the critical promoter AP1 
binding site disclosed by the reported experiments. We isolated, mapped, and 
functionally characterized the 5’-flanking region of the rat Lot1 gene. By both 5’-
deletion analysis and site mutagenesis of the native Lot1 promoter, we directly 
demonstrated that the AP1 binding site at -268 bp from the transcription start site is 
necessary to achieve a full transcriptional response to cAMP elevation by forskolin 
stimulation. Moreover, our results show that cAMP elevation by forskolin up-
regulated the expression of c-Fos, implicating this immediate-early gene as the 
transcriptional mediator linking ERK1/2 phosphorylation to Lot1 promoter activation. 
Our data show, however, that overexpression of c-Fos alone was not sufficient to 
activate the Lot1 promoter, but cotransfection of c-Jun and c-Fos together resulted in 
significant induction of Lot1 promoter activity. Overexpression of other heterodimers 
such as c-Fos/JunB and c-Jun/JunB was not effective. The unique role of the c-Fos/c-
Jun heterodimer in activation of the AP1 complex on the Lot1 promoter is supported 
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by A-Fos overexpression studies. Putative knockout of the AP1-binding activity by 
overexpression of A-Fos was effective in blocking activation of Lot1 promoter 
activity. This dominant interfering mutant has been shown previously to disrupt c-
Fos/c-Jun heterodimer binding to DNA in a remarkably specific manner (Olive et al., 
1997).  
Our results provide novel information on the functional significance of the up-
regulation of Lot1 expression by cAMP stimulation in CGC. First, we have shown 
that Lot1 is induced in CGC by the anti-mitogenic and differentiative stimulus 
exerted by PACAP and cAMP on these neuronal cells. Second, our analysis revealed 
that the cellular mechanisms regulating Lot1 activation, i.e. the PKA-MEK-ERK 
cascade and c-Fos induction, are the same that regulate crucial steps of the 
neurogenetic process (Moody et al., 2003). Third, the characterization of these 
mechanisms, together with the previous data on Lot1 expression in brain 
development, enforces the notion that the gene may play an essential role in 
neurogenesis, with particular reference to cerebellar development (Ciani et al., 2003). 
Fourth, regulation of the Lot1 gene, described here for neuronal cells, may be 
different in other cell types. It has been indeed noted in the Introduction that Lot1 acts 
as a tumor suppressor gene in cancer cells (Pagotto et al., 1999; Spengler et al., 
1997). With the present observations, we have shown that the epithelial cell line 
HEK293 responds to cAMP elevation in a very different way compared with CGC 
and that c-Fos induction is not part of the signaling elicited in these cells. Thus, 
depending upon the availability of AP1 protein factors, the dimerization among 
different members of the AP1 family might lead to different regulatory effects on 
Lot1 expression. These studies clearly indicate a possible role for Lot1 gene 
expression controlled by different stimuli in regulating proliferation of neuronal 
precursors and brain development.  
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